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Resumo 
 A nefropatia diabética é uma das maiores complicações diabéticas 
microvasculares e é a principal causa de doença renal em estado terminal. Cerca de 80% 
de pessoas não tratadas com diabetes tipo 1 e microalbuminúria desenvolvem nefropatia, 
e uma percentagem significativa de pacientes com diabetes tipo 2 (20-40%) são 
susceptíveis ao desenvolvimento da doença. Esta patologia é caracterizada por uma 
acumulação excessiva de matriz extracelular, com espessamento da membrana basal 
glomerular e hipertrofia de vários tipos de células glomerulares e tubulares, que acaba por 
progredir para glomerulosclerose e fibrose túbulo-intersticial. Existem evidências que 
sugerem um envolvimento do stresse do retículo endoplasmático no desenvolvimento de 
nefropatia diabética, mas os mecanismos moleculares subjacentes permanecem por 
clarificar. 
 Tal como acontece com todas as complicações da diabetes, a hiperglicemia activa 
uma série de alterações no rim, que levam á disfunção glomerular e tubular e acelera a 
apoptose celular. Portanto, terapias anti-diabéticas obtendo um bom controlo glicémico 
diminuem o risco para o desenvolvimento da nefropatia diabética. A sitagliptina faz parte 
de uma nova classe de anti-hiperglicémicos orais, os inibidores da DPP-IV, os quais 
melhoram o controlo glicémico através de um aumento da secreção de insulina nos 
pacientes com diabetes do tipo 2 potenciando um sistema fisiológico, o efeito incretina. 
Até ao início deste trabalho a informação existente sobre os potenciais efeitos 
benéficos da sitagliptina na atenuação/reversão de algumas das lesões no rim induzidas 
pela diabetes era escassa. Nesse contexto, o objectivo deste estudo foi avaliar a 
capacidade desse fármaco na atenuação das complicações microvasculares no rim, num 
modelo animal de diabetes do tipo 2, os ratos ZDF (fa/fa). Às 26 semanas de idade, estes 
animais diabéticos apresentaram alterações nos estados inflamatório e apoptótico. A 
imunoreactividade das citocinas pró-inflamatórias IL-1β e TNF aumentou em células 
localizadas ao redor do glomérulo, provavelmente células tubulares e/ou células 
inflamatórias intersticiais. A hiperglicemia crónica induziu também um aumento 
significativo na razão BAX/Bcl-2, acompanhado por um aumento dos níveis da proteína 
pro-apoptótica Bid, mostrando que a diabetes promove um carácter pro-apoptótico no 
rim. Estes animais diabéticos apresentaram ainda um aumento significativo nos níveis 
proteicos da P-Akt no rim, associada a hipertrofia de células mesangiais e expansão da 
matriz extracelular. Dados preliminares mostraram que a diabetes parece aumentar a 
x 
 
capacidade de translocação da CHOP e ATF4 para o núcleo, dois factores de transcrição 
relacionados com o stresse do retículo endoplasmático; no entanto, não houve alterações 
significativas nos níveis totais das proteínas CHOP e GRP78/BiP no rim de animais 
diabético. 
No grupo de animais diabéticos, a administração da sitagliptina promoveu uma 
melhoria no controlo glicémico, após 6 semanas de tratamento. A sitagliptina aumentou 
significativamente os níveis proteicos de GLP-1 no rim, acompanhado por uma 
diminuição na imunoreactividade de GLP-1R, provavelmente devido a um feedback 
negativo. Relativamente às citocinas pro-inflamatórias, a sitagliptina diminuiu 
acentuadamente a imunoreactividade de IL-1β e TNF no rim de animais diabético, assim 
como preveniu o aumento da razão BAX/Bcl-2 e dos níveis proteicos de Bid. A 
sitagliptina também diminuiu os níveis de P-Akt no rim dos animais diabéticos. 
Curiosamente, a administração de sitagliptina promoveu um aumento significativo nos 
níveis da proteína CHOP, no entanto a translocação de CHOP e ATF4 para o núcleo 
parece diminuir. 
Em suma, podemos concluir que o tratamento de sitagliptina tem efeitos benéficos 
no rim, possivelmente por mecanismos que envolvem uma melhoria das lesões renais, 
com consequente redução da apoptose e inflamação. Adicionalmente, resultados 
preliminares obtidos neste estudo sugerem que a sitagliptina poderá alterar a resposta do 
stresse do retículo endoplasmático. No entanto, estudos futuros serão necessários para 
uma melhor compreensão dos mecanismos moleculares e celulares envolvidos nas acções 
directas mediadas pela sitagliptina no rim, os quais poderão contribuir para o 
desenvolvimento de novas estratégias terapêuticas mais eficazes e direccionadas para a 
prevenção ou redução do efeito nocivo da hiperglicemia crónica nas células do rim. 
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Abstract 
Diabetic nephropathy is one of the major microvascular diabetic complications 
and is the leading cause of end-stage renal disease. About 80% of untreated people with 
type 1 diabetes and microalbuminuria progress to overt nephropathy, and a significant 
percentage of patients with type 2 diabetes (20-40%) are susceptible to the development 
of disease. This pathology is characterized by excessive accumulation of extracellular 
matrix, with thickening of glomerular basement membrane and hypertrophy of various 
cell types of the glomerulus and tubules, which ultimately progress to glomerulosclerosis 
and tubulointerstitial fibrosis. There are evidences that suggest an involvement of ER 
stress in the development of diabetic nephropathy, but the underlying molecular 
mechanisms remain unclear. 
As in all complications of diabetes, hyperglycaemia promotes a series of changes 
in the kidney, that lead to glomerular and tubular dysfunction and accelerating cell 
apoptosis. Therefore, anti-diabetic therapies achieving a good glycaemic control reduce 
the risk for the development of diabetic nephropathy. Sitagliptin is part of a new class of 
oral anti-hyperglycaemic agents, the DPP-IV inhibitors, which improves glycaemic 
control by increasing insulin secretion in patients with type 2 diabetes enhancing a 
physiological system, the incretin effect. 
At the beginning of this work the existing information on the potential beneficial 
effects of sitagliptin in the attenuation/reversal of some of the kidney lesions induced by 
diabetes was scarce. In this context, the aim of this study was to assess the ability of this 
compound in the attenuation of microvascular complications in the kidney, in an animal 
model of type 2 diabetes, ZDF (fa/fa) rats. At 26 weeks of age, these animals showed 
changes in inflammatory and apoptotic states. The immunoreactivity of the 
proinflammatory cytokines IL-1β and TNF was increased in cells around the glomeruli, 
probably tubular cells and/or interstitial inflammatory cells. Chronic hyperglycaemia also 
induced a significant increase in BAX/Bcl-2 ratio, accompanied by an increase in the 
levels of pro-apoptotic protein Bid, showing that diabetes increases the pro-apoptotic state 
in the kidney. These diabetic animals also showed a significant increase in P-Akt protein 
levels in the kidney, associated with mesangial cells hypertrophy and extracellular matrix 
expansion. Preliminary data show that diabetes seems to increase the capacity in 
translocation of CHOP and ATF4, transcription factors associated with the ER stress, to 
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the nucleus; however, there were no significant changes in the total levels of CHOP and 
GRP78/BiP proteins in the diabetic kidney.  
In the diabetic animal group, administration of sitagliptin promoted an 
improvement in glycaemic control after 6 weeks of treatment. Sitagliptin significantly 
increased the GLP-1 protein levels in the kidney, accompanied by a decrease in the 
immunoreactivity for GLP-1R, probably due to a feedback mechanism. Concerning the 
proinflammatory cytokines, sitagliptin markedly decreased the immunoreactivity of IL-1β 
and TNF in the diabetic kidney, as well as prevented the increase of BAX/Bcl-2 ratio and 
Bid protein levels. Sitagliptin also decreased the P-Akt protein levels in the kidney of 
diabetic animals. Interestingly, the administration of sitagliptin promoted a significant 
increase in CHOP protein levels, however, CHOP and ATF4 translocation to the nucleus 
seems to decrease. 
 Overall, we can conclude that sitagliptin treatment has beneficial effects on the 
kidney, possibly by mechanism involving an improvement in renal lesions with 
consequent reduction in apoptosis and inflammation. Additionally, the preliminary results 
obtained in this study suggest that sitagliptin could modulate the ER stress response. 
However, further studies are needed to better understand the molecular and cellular 
mechanisms involved in the direct actions mediated sitagliptin in the kidney, which may 
contribute to the development of new therapeutic strategies more effective and focused on 
preventing or reducing the injurious effects of chronic hyperglycaemia on cells of the 
kidney. 
 
Key words: Diabetic nephropathy, Sitagliptin, Dipeptidyl peptidase-IV, Incretins, ER 
stress, Inflammation, Apoptosis. 
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1. Diabetes Mellitus 
1.1. General definition and epidemiology 
Diabetes mellitus (DM) has been defined as a complex and heterogeneous 
metabolic disorder, which is mainly characterized by chronic hyperglycaemia, with 
abnormal metabolism of carbohydrates, lipids and proteins, resulting from defects in 
insulin secretion and/or insulin action (Alberti et al., 1998). The effects of DM include 
long-term dysfunction and failure of various organs and tissues, with progressive 
development of specific complications. 
Several pathogenic processes are involved in the development of diabetes. These 
include processes which destroy the β-cells of the pancreas with consequent insulin 
deficiency, and others that result in resistance to insulin action (Rossetti et al., 1990; 
Zimmet et al., 2001). 
DM prevalence rates have risen markedly in recent years. According to the 
International Diabetes Federation (IDF), DM is one of the most common non-
communicable diseases, with high rates of morbidity and mortality, recording about 4.8 
million deaths in 2012. At present, diabetes affects about 371 million people (Figure 1) 
and it is estimated to increase to 552 million by 2030, thus representing 8.3% of the adult 
population. However, these numbers are underestimated due to the high rate of 
undiagnosed diabetes in patients, which represents half of people with the disease (IDF, 
2012). 
Recent estimates for 2011 from the Portuguese Society of Diabetology have 
indicated that 12.7% of portuguese adult population is diabetic, from which 5.4% were 
undiagnosed (OND, 2012). 
The prevalence of diabetes is reaching pandemic proportions on a global scale, 
becoming a threat to public health throughout the world, highlighting the importance of 
implementing effective preventive and therapeutic strategies (Zimmet et al., 2001; 
Hossain et al., 2007).  
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Figure 1: Global prevalence (%) of diabetes mellitus in adult population (20-79 years) in 2012, shown 
by geographic region (Image taken from IDF Diabetes Atlas, 5
th
 Edition (IDF, 2012)). 
 
 DM is a multifactorial disease in which multiple genetic and environmental 
factors contribute to its onset and progression. The concomitant increase in life 
expectancy, obesity, sedentary lifestyle, hypertension and hyperlipidemia might raise the 
chance of citizens from both developed and developing countries of having glucose 
intolerance. This suggests that diabetes is certainly one of the most challenging health 
problems in the 21
st
 century (Zimmet et al., 2001; Tuomi, 2005). 
 
1.2. Characterization of diabetes mellitus 
According to the WHO and IDF there are three main types of diabetes, as follows: 
type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM) and gestational 
diabetes. However, most prevalent forms of diabetes are T2DM, known as insulin-
resistant, representing about 90% of the cases, and T1DM, also called insulin-dependent, 
responsible for 5-10% of the cases (Zimmet et al., 2001).  
DM is associated with a decreased of pancreatic β-cell, due to cell death by 
apoptosis and defective β-cell regeneration, which are mediated by activation of 
metabolic pathways, in response to chronic hyperglycaemia condition (Cnop et al., 2005). 
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1.2.1. Type 1 diabetes mellitus (T1DM) 
 T1DM usually occurs in young subjects, and is an autoimmune disease 
characterized by progressive destruction of pancreatic β-cells and multiple genetic 
predispositions and environmental factors seems to be associated with the suppression of 
insulin synthesis. T1DM patients are, therefore, dependent on exogenous insulin to 
maintain adequate insulin levels, which leads to better control of blood glucose levels 
(Cnop et al.; 2005; Ichinose et al., 2007). 
 
1.2.2. Type 2 diabetes mellitus (T2DM) 
 T2DM is one of the most prevalent and serious metabolic diseases in the world. It 
occurs predominantly in adults (people older than 40 years); however, there has been a 
rise in diagnosed cases of T2DM among people with younger ages, suggesting an 
association with the increase of childhood obesity (Hossain et al., 2007). Insulin 
resistance and pancreatic β-cell dysfunction are the hallmarks of this disease. 
T2DM has higher prevalence than T1DM, due to sedentary lifestyle, lack of 
physical activity, increasing obesity and unhealthy diet (Houssain et al., 2007; Villary et 
al., 2007). 
 In the early stage of T2DM, there is a state of insulin resistance, leading to 
qualitative and quantitative changes in its secretion. Insulin resistance is defined as the 
inability of insulin (endogenous and exogenous) to promote glucose cell uptake, resulting 
in elevated blood glucose (hyperglycaemia) (Villary et al., 2007). As a consequence of 
hyperglycaemia, there is a compensatory increase of insulin secretion by pancreatic β-
cells (hyperinsulinaemia), in order to maintain normoglycaemia, a process termed β-cell 
compensation. This process declines β-cell secretory capacity, leading to eventual failure 
and progressive loss of these cells (Butler et al., 2003; Virally et al., 2007). 
 
1.3. Diabetic complications 
 Diabetics can live for years without showing any symptoms, during which high 
glucose levels will silently damage several organs. The frequency, severity and 
progression of diabetic complications are related with several factors, such as levels of 
CHAPTER 1 – Introduction and Aims 
6 
 
hyperglycaemia, metabolic changes associated with the duration of disease, exposure to 
risk factors and also with genetic environment. 
 Patients with a diagnosis of diabetes can have many macrovascular 
(atherosclerosis, stroke, coronary heart disease, acute myocardial infarction, peripheral 
vascular disease) and microvascular (retinopathy, nephropathy or peripheral neuropathy) 
complications (Figure 2) (Fowler, 2008; Calcutt et al., 2009). 
 These complications have been directly associated with glucose toxicity and 
activation of several intracellular metabolic pathways, including increased protein 
glycosylation, abnormal activation of signaling cascades, such as protein kinase C (PKC), 
increased activation of hexosamine and polyol pathways, and elevated production of 
reactive oxygen species (ROS) (Giacco and Brownlee, 2010). Moreover, accumulating 
evidence suggests that inflammation and endoplasmic reticulum (ER) stress also plays an 
important role in the pathogenesis of diabetes (Saraheimo et al., 2003; Eizirik et al., 
2008). 
 DM and its complications have become a major public health problem, 
highlighting important research advances and the development of novel methods to both 
prevent and treat this disease. 
 
 
Figure 2. Schematic diagram of macro and micro complications of diabetes (Adapted from Cefalu and 
Canon, 2007). 
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2. Diabetes and the kidney 
2.1. Kidney anatomy and function 
The kidney is one of the most complex and dynamic organs of human body and 
plays an essential role in maintaining body homeostasis through excretion of waste 
products and excess water in the form of urine, regulating the chemical composition of 
the blood by controlling the fluid, electrolyte and acid-base balance of the circulation 
system, and producing hormones that help to maintain blood pressure, keep healthy bones 
and prevent anemia (Brenner, 2000). 
The kidney has a high content of epithelial cells with extensive intracellular 
membrane trafficking machinery. The basic functional unit of the kidney is the nephron 
(Figure 3), and each kidney contains approximately 0.5-1 million nephrons, which are 
responsible for blood filtration and urine production (Roestenberg, 2006; Dankers et al., 
2011). The nephron consists of a glomerulus, surrounded by parietal epithelial cells of 
Bowman’s capsule, a proximal tubule, a loop of Henle and a distal tubule that is 
connected to a collecting duct. Nephrons remove excess water and soluble matter from 
the body by first filtering the blood, and then reabsorbing some necessary fluid and 
molecules back into the blood while secreting other unneeded molecules (Dankers et al., 
2011).  
 
Figure 3. The basic functional unit of the kidney - Nephron 
(Adapted from http://health.rush.edu/HealthInformation/BodyGuide/reftext/html/urin_sys_fin.html). 
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Glomerulus consists of a capillary tuft enclosed in Bowman’s capsule, and the 
capillaries are enclosed by specialized visceral epithelial cells, named podocytes (Figure 
4) (Roestenberg, 2006). The endothelial cells of the glomerulus and the podocytes are 
separated by a glomerular basement membrane (GBM), which is composed of 
extracellular matrix (ECM) proteins, such as collagen IV, and negatively charged 
glycoproteins, such as heparin sulfate proteoglycans (Dankers et al., 2011). Podocytes 
form a crucial component of the glomerular filtration barrier. The glomerular filtration 
barrier is characterized by extensive interdigitating foot processes, that are separated by 
narrow spaces with a constant width of 40 nm, called slit diaphragm, which are pores 
composed by specific proteins and are freely permeable to water and small solutes but 
selectively impermeable to plasma proteins (Tryggvason, 1999; Wartiovaara et al., 2004). 
Furthermore, it has been reported that nephrin, a protein of slit diaphragm of glomerular 
podocytes, is crucial for maintaining the integrity of the slit diaphragm structure and an 
intact filtration barrier (Ruotsalainen et al., 1999). Functionally, podocytes are 
responsible for the GBM turnover, maintenance of the filtration barrier, support of the 
capillary tuft and regulation of the glomerular filtration (Leewis et al., 2010). 
 
 
 
Figure 4. Schematic representation of a glomerulus (Image taken from Leeuwis et al., 2010) 
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Another cell type found in glomerulus is the mesangial cell. These cells are in 
direct contact with the capillaries and are essential for maintaining the structural and 
functional dynamic stability of glomerular tufts, providing structural support for capillary 
loops and modulating glomerular filtration (El-Nahas, 2003). Mesangial cells produce 
ECM and are separated from podocytes by the GBM. These cells regulate wall tension 
and intracapillary flow, as well as produce many growth factors and other proteins that 
are important for the normal physiological function of the podocytes and glomerular 
endothelial cells (Schlӧndorff and Barnas, 2009). 
 
2.2. Diabetic nephropathy 
2.2.1. Prevalence 
 Diabetic nephropathy (DN) is one of the major microvascular complications of 
both types 1 and 2 diabetes, which can result in end-stage renal disease (ESRD), requiring 
dialysis or transplantation (Dronavalli et al., 2008; Kanwar et al., 2008). This stage of 
advanced chronic renal failure contributes to the decrease of quality of life and 
significantly shortened life expectancy of the patients, conferring high morbidity and 
mortality rates of diabetic patients, as well as contributes to rising medical costs. In 
addition, chronic kidney disease also contributes to the development of cardiovascular 
disease which leads to an increase in mortality rates (Go et al., 2004; Zeeuw et al., 2006). 
About 20-40% of the diabetic patients develop microalbuminuria, a sign of nephropathy 
(Dronavalli et al., 2008), mostly within 15-20 years after diagnosis (Parving et al., 1988; 
Ismail et al., 1999).  
 The incidence rate of ESRD has been increasing in worldwide (Xue et al., 2001; 
Wakai et al., 2004), and the clinical history of DN differs according to the type of 
diabetes. About 80% of untreated people with T1DM and microalbuminuria progress to 
overt nephropathy, whereas only 20-40% of those with T2DM are susceptible to the 
development of disease (Dronavalli et al., 2008). Although the highly probability of 
T1DM patients to develop DN, the T2DM patients constitute the majority of diabetic 
people with this pathology, because of the much greater prevalence of this type of 
diabetes (Ritz et al., 1999). 
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2.2.2. Pathophysiology of the diabetic nephropathy 
DN is characterized by a progressive renal disease with functional and structural 
abnormalities, and hyperglycaemia is the driving force for the development of this 
pathology, inducing metabolic and hemodynamic factors that are mediators of this injury. 
Moreover, several genes have been associated with susceptibility for development of DN 
(Tanaka and Babazono, 2005).  
 DN has several distinct phases of development and multiple mechanisms can 
contribute to the development of the disease and its outcomes, through damage of various 
cells, including glomerular podocytes, mesangial and endothelial cells, and tubular 
epithelia. The early stage of DN is characterized by glomerular hyperfiltration (increased 
urine production) represented by high values of glomerular filtration rate (GFR) (Chawla 
et al., 2010), leading to the development of microalbuminuria (30-300 mg/day or 20 
µg/min) (Dronavalli et al., 2008), and is also associated with development of other 
complications, such as cardiovascular disease (Go et al., 2004; Zeeuw et al., 2006). The 
morphological changes of the kidney for these functional abnormalities include 
glomerular and tubular epithelial hypertrophy, thickening of GBM and expansion of 
mesangial ECM (Figure 5) (Adler, 1994; Chawla et al., 2010). Decreased levels of 
nephrin are also connected to the early changes of DN, and may contribute to the loss of 
glomerular filtration function (Aaltonen et al., 2001). Advanced DN is characterized by 
glomerulosclerosis, demise of glomerular capillaries, tubulointerstitial degeneration and 
fibrosis, associated with precipitous decline of GFR, developing macroalbuminuria (>300 
mg/day or >200 µg/min) (Dronavalli et al., 2008), leading to chronic renal insufficiency 
that declines to ESRD.   
 Several factors have been shown to influence the renal cells loss and progression 
of DN, such as hyperglycaemia-induced metabolic and hemodynamic factors (Vinod, 
2012), as well as hyperlipidemia (Kasiske et al., 1988) and ER stress (Cunard and 
Sharma, 2011). In diabetic patients, instead of dumping glucose in the urine to correct 
hyperglycaemia, the kidney chooses to hold on to the glucose. The ability of the kidney to 
reabsorb glucose is augmented by an absolute increase in the renal glucose influx 
capacity, possibly by GLUT-1, a surface receptor of resident renal cells, which is 
overexpressed in mesangial cells under high glucose concentrations (Heilig et al., 1997), 
associated with overexpression of transforming growth factor-β1 (TGF-β1) (Inoki et al., 
1999). 
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The hemodynamic factors implicated in the pathogenesis of DN include increased 
systemic and intraglomerular pressure, as well as hyperfiltration and hyperperfusion 
injuries, through activation of various vasoactive hormone pathways, including the renin-
angiotensin system (RAS), specifically angiotensin-II (ANG-II), and endothelins 
(Ichinose et al., 2007; Dronavalli et al., 2008). In fact, ANG-II stimulates resident renal 
cells to produce TGF-β1 that induces mesangial expansion and GBM thickening, through 
augmentation of  ECM protein deposition, such as collagen types I, IV, V and VI, and 
fibronectin (Schena and Gesualdo, 2005), and is also been implicated in production of 
monocyte chemoattractant protein 1 (MCP-1) and ROS (Chawla et al., 2010). Moreover, 
Akt signaling has an emerging role in pathogenesis of DN, namely in mesangial 
hypertrophy and ECM composition (Zdychova and Komers, 2004; Alique et al., 2011; 
Kattla et al., 2008). Several studies have described increased Akt activity in diabetic 
kidney (Feliers et al., 2001). Additionally, diverse factors including vascular endothelial 
growth factor (VEGF), prostanoids and diverse cytokines have also been implicated in 
hyperfiltration injury and increased vascular permeability (Wolf, 2004). 
 
 
 
Figure 5. Characteristic glomerular changes in DN. (a) Normal glomerulus. (b) Diabetic kidney: 
thickening of GBM and mesangial expansion, due to increased mesangial matrix and increased mesangial 
cell size due to hypertrophy, as well as a reduction in podocytes number. (Image taken from Jefferson et al., 
2008) 
 
Moreover, it is well known that hyperglycaemia increases oxidative stress, 
inflammation and activate several metabolic pathways, such as non-enzymatic 
glycosylation, activation of PKC, polyol pathway and hexosamine biosynthetic pathway, 
which contribute to the development and pathogenesis of DN. 
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2.2.3. Oxidative stress 
 Another contributing mechanism for renal injury is the oxidative stress that results 
from enhanced reactive oxygen species (ROS) generation and decreased antioxidant 
defense system. Chronic hyperglycaemia has been indicated as one of the major causes 
that lead to oxidative stress, due to activation of several pathways, uncoupled endothelial 
nitric oxide synthase (eNOS) activity, oxidative metabolism of glucose in the 
mitochondria and glucose auto-oxidation (Evans et al., 2002; Susztak et al., 2006).  
 ROS are chemical compounds that result from the activation or reduction of 
molecular oxygen or derivatives of the products of this reduction, such as the superoxide 
anion (O2
●-
) and hydroxyl radical (OH
●
) (Irani, 2000; Evans et al., 2002). Excessive 
levels of ROS lead to the damage of proteins, lipids and deoxyribonucleic acid (DNA), 
and also play a significant role in the activation of stress-sensitive signaling pathways that 
regulate gene expression resulting in cellular damage (Melov et al., 1999; Drӧge, 2002; 
Evans et al., 2002). Therefore, in order to maintain proper cellular function and 
homeostasis, has to be fulfilled a balance between ROS production and consumption. 
However, hyperglycaemia has been shown to induce a decrease in antioxidant capacity, 
through a decline in important cellular antioxidant defense mechanisms, which 
significantly increases the susceptibility to oxidative stress (Wolff et al., 1991). These 
antioxidant defense mechanisms involve an enzymatic strategy, including the enzymes 
superoxide dismutase (SOD), catalase and glutathione peroxidase, and non-enzymatic 
components, such as vitamins A, C and E, and also the α-lipoic acid (Maritim et al., 
2002). In addition, reduced glutathione (GSH) is an important scavenger of ROS, and, 
due to the fact that nicotinic acid adenine dinucleotide phosphate (NADPH) is consumed 
by glucose reduction to sorbitol, and since NADPH is required for regenerating GSH, this 
could induce intracellular oxidative stress (Giacco and Brownlee, 2010). Recent 
evidences suggest that NADPH oxidase is the primary source of vascular and renal ROS 
production (Shi et al., 2008). Furthermore, the increased oxidative stress in diabetes has 
been associated with mitochondrial superoxide anion overproduction, which is the central 
and major mediator for the activation of several metabolic pathways, as before referred 
(Du et al., 2000; Nishikawa et al., 2000). Increased superoxide production is also 
correlated with endothelial dysfunction, through inactivation of the eNOS (Guzik et al., 
2002). Oxidative stress is not only associated with complication of diabetes, but also with 
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insulin resistance and pancreatic β-cell dysfunction (Evans et al., 2002), and has been 
linked to lipid-induced ER stress (Borradaile et al., 2006).  
Oxidative stress is strongly correlated with the development of DN. Enhanced 
ROS production have been linked to vasoconstriction, endothelial dysfunction, 
modification of ECM proteins and increased renal sodium reabsorption (Elmarakby and 
Sullivan, 2010). The importance of oxidative stress in DN is underscored by the finding 
that inhibition of oxidative stress ameliorates the manifestations associated with diabetes-
induced kidney injury. In fact, inhibition of hyperglycaemia-induced superoxide 
overproduction using a transgenic approach (overexpression of SOD) prevents long-term 
DN (Craven et al., 2001; DeRubertis et al., 2004). Additionally, it has been demonstrated 
that glucose-induced ROS production initiates podocyte apoptosis and podocyte depletion 
in vitro and in vivo, leading to DN (Susztak et al., 2006). 
  There is also been described a link between oxidative stress and inflammation in 
diabetic kidney. Oxidative stress can increase cytokines production via the activation of 
nuclear factor κB (NF-κB) (by degradation of NF-κB inhibitors (IκB)) and activator 
protein 1 (AP1), leading to the transcription of genes encoding cytokines and growth 
factors, such as interleukins (IL-1, -6 and -18) and transforming growth factor-β (TGF-β) 
(Elmarakby and Sullivan, 2010). 
 
2.2.4. Inflammation 
 DM is not only a metabolic disorder, several studies have shown that there is a 
correlation between inflammatory and metabolic processes involved in diabetes, 
developing and exacerbating the level of microvascular complications, such as DN. 
Therefore, an association between DN and the presence of a chronic low-grade 
inflammation was established (Saraheimo et al., 2003; Dalla Vestra et al., 2005). 
Moreover, a state of inflammation is also commonly associated with obesity and insulin 
resistance in T2DM (Shoelson et al., 2006). Elevated inflammatory mediators cause 
insulin resistance since they reduce the insulin receptor substrate 1 (IRS-1) tyrosine 
phosphorylation and the activation of phosphoinositide 3-kinase (PI3K) and Akt3k, 
decreasing insulin signaling (Jager et al., 2007).  
 Accumulating evidence indicates that immunologic and inflammatory 
mechanisms play a significant role in the development and progression of DN. This 
inflammatory response is mediated by diverse inflammatory cells, including 
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macrophages, monocytes and leukocytes (Chow et al., 2004; Galkina and Ley, 2006), as 
well as other molecules, such as chemokines (MCP-1) (Chow et al., 2006), adhesion 
molecules intercellular adhesion molecule 1 (ICAM-1) (Chow et al., 2005) and 
inflammatory cytokines, mainly tumor necrosis factor (TNF), C-reactive protein (CRP), 
TGF-β, interleukin-6 (IL-6), interleukin-1β (IL-1β) and interleukin-18 (IL-18) (Navarro 
and Mora, 2006). There is also an association between oxidative stress and inflammation, 
as oxidative stress can stimulate cytokines production (Elmarakby and Sullivan, 2010), 
and, on the other hand, it is known that inflammatory mediators can trigger ROS 
production. 
 The NF-κB is a transcription that regulates the gene expression of several 
molecules involved in inflammation, such as ICAM-1, MCP-1, TGF-β, IL-1β and TNF 
(Guijarro and Egido, 2001). In fact, it has been reported that the inhibition of NF-κB 
activity significantly decreases the expression of proinflammatory cytokines in diabetic 
kidney, such as ICAM-1 and MCP-1, as well as TGF-β1 (Soetikno et al., 2011). NF-κB is 
suggested to play an important role in mesangial cell activation leading to renal injury and 
NF-κB expression is increased in diabetic kidney (Massy et al., 1999). Furthermore, 
MCP-1 is responsible for macrophage recruitment, leading to development of renal 
fibrosis and, indirectly, ECM formation (Tesch, 2008). 
 Although the proinflammatory cytokine TNF is mainly synthesized by monocytes 
and macrophages, various renal cells, including tubular, glomerular, mesangial and 
endothelial cells, are also able to produce this cytokine (Jevnikar et al., 1991; Nakamura 
et al., 1993; Hasegawa et al., 1995). TNF induces the expression of other cytokines, 
chemokines and adhesion molecules (Ortiz et al., 1995), and it was also described that 
this proinflammatory mediator induces oxidative stress in diverse cells, including 
mesangial cells, by promoting the local generation of ROS (Radeke et al., 1990). 
Moreover, this cytokine stimulates sodium uptake by proximal tubule cells, contributing 
to sodium retention and renal hypertrophy (Melnikov et al., 2002). Overall, TNF is 
cytotoxic to glomerular, mesangial and epithelial cells, and induce direct renal damage, 
contributing to the development of DN.  
 It has been described that interleukine-1 (IL-1) stimulates the proliferation of 
mesangial cells and matrix synthesis and enhances vascular endothelial permeability 
(Melcion et al., 1982; Royall et al., 1989), as well as induces the expression of ICAM-1 
and vascular cell adhesion molecule-1 (VCAM-1) by glomerular endothelial cells 
(Navarro-González and Mora-Fernández, 2008). IL-6 also stimulates proliferation of 
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mesangial cells and enhances endothelial permeability, as well as increases fibronectin 
expression and affects ECM dynamics at both mesangial and podocyte levels (Vestra et 
al., 2005; Navarro and Mora, 2006). 
 Other potent inflammatory cytokine implicated in inflammatory process in 
diabetic kidney cells is IL-18. This cytokine induces the production of interferon gamma 
(IFN-γ) (Okamura et al., 1995), that in turn modulates functional chemokine receptor 
expression in human mesangial cells (Schwarz et al., 2002), and also stimulates other 
cytokines production, such as IL-1 and TNF, regulates ICAM-1 and induces apoptosis of 
endothelial cells (Navarro-González and Mora-Fernández, 2008). 
  
Overall, the increased expression of cytokines, chemokines and adhesion 
molecules, and inflammatory cells recruitment, may be a critical factor for the 
development of microvascular complications associated with diabetes. 
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3. Endoplasmic reticulum and diabetes 
3.1. Endoplasmic reticulum stress 
 The endoplasmic reticulum (ER) is a highly dynamic central cellular organelle 
equipped with chaperones and folding enzymes, being responsible for the synthesis, 
folding and post-translational modifications of secretory and trans-membrane proteins, 
and lipid biosynthesis (Eizirik et al., 2008). This organelle also functions as a dynamic 
calcium store and signaling, controlling a wide range of cellular processes such as 
organogenesis, transcriptional activity, stress responses and apoptosis (Zhang and 
Kaufman, 2008). Therefore, the efficient functioning of the ER is essential for most 
cellular activities and survival. 
 The unique oxidizing environment of the ER and the numerous protein chaperones 
present in the organelle are crucial for the proper folding of proteins and protein 
complexes. This organelle is exquisitely sensitive to alterations in homeostasis and 
environmental insults (Eizirik et al., 2008). Thus, pathophysiological stress conditions, 
such as hypoxia, hyperglycaemia, elevated protein synthesis, ER-calcium depletion, 
nutrient excess or deprivation, altered protein glycosylation and glucose starvation, 
interfere with the correct folding of proteins (Asada et al., 2011; Eizirik et al., 2008; 
Cunard and Sharma, 2011; Chiang et al., 2012). Accumulation of misfolded and unfolded 
proteins in the ER lumen induces their aggregation, causing an imbalance in protein-
folding capacity and protein-folding load, and subsequent cellular toxicity (Eizirik et al., 
2008; Cunard and Sharma, 2011), a condition referred as ER stress. 
 The ER responds to these perturbations by activating an intracellular signaling 
pathway, called the unfolded protein response (UPR), to ensure the fidelity of protein 
folding and to prevent such an accumulation of unfolfed or misfolded proteins (Ezirik et 
al., 2008; Cunard and Sharma; 2011). Activation of the UPR leads to a transient 
translational attenuation, transcriptional induction of genes encoding ER-resident 
chaperones and ER-associated protein degradation (ERAD) (Schrӧder and Kaufman, 
2005; Ron and Walter, 2007) 
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3.1.1. Unfolded protein response 
The concept of an UPR pathway, which first appeared in the literature in 1988, 
had its origin in experiments performed by Kozutsumi et al. (1988), in which mammalian 
cells exposed to severe ER conditions, such as altered pH, low levels of glucose or 
oxygen, or alterations in the oxidizing state of the ER responded by up-regulating the ER 
chaperones, including glucose-regulated protein 78 (GRP78/BiP) (Kozutsumi et al., 
1988). 
In resting, unstressed cells, GRP78/BiP binds to the ER luminal domains of the 
ER stress sensors inositosol requiring 1α (IRE1α), PKR-like ER kinase (PERK) and 
activating transcription factor 6 (ATF6) and maintains them in an inactivated state 
(Schrӧder and Kaufman, 2005). During ER stress, GRP78/BiP preferentially binds to 
unfolded and misfolded proteins and dissociates from the transmembrane sensors, 
facilitating their activation (Ni and Lee, 2007). After GRP78/BiP dissociation, it is not 
clear whether full activation of the ER stress response requires subsequent binding of 
unfolded proteins to the luminal domains of IRE1α, PERK and ATF6 (Ron and Walter, 
2007).  
The primary purpose of the UPR is to facilitate adaptation to the changing 
environment and reestablish normal ER function. The UPR is activated when misfolded 
and unfolded proteins accumulate in the ER lumen, and consist mainly of three simple 
adaptive mechanisms: 1) upregulation of the folding capacity of the ER through induction 
of ER-resident molecular chaperones, including GRP78/BiP (Ni and Lee, 2007; Ron and 
Walter, 2007), 2) down-regulation of the biosynthetic load of the ER through shut-off of 
protein synthesis on a transcriptional and translational level, and 3) increased clearance of 
unfolded proteins from the ER through upregulation of ERAD, thus preventing additional 
protein misfolding and overloading of the organelle (Ron and Walter, 2007; Eizirik et al., 
2008). ERAD mediates the retro-translocation of unfolded proteins from the ER lumen 
into the cytosol for degradation by the proteasome (Ron and Walter, 2007). However, if 
these three mechanisms do not restore ER homeostasis and ER stress persists, the UPR 
can activate a cell death pathway, by switching from pro-survival to pro-apoptotic 
signaling (Rao et al., 2002; Szegezdi et al., 2006), presumably to protect the organism 
from rogue cells that display misfolded proteins (Schrӧder and Kaufman, 2005; Ron and 
Walter, 2007). 
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GRP78/BiP has a conserved N-terminal ATPase domain and a C-terminal peptide 
binding domain (Ni and Lee, 2007). The region of GRP78/BiP that associates with ER 
stress sensors is its peptide-binding region that is the same region that binds to exposed 
hydrophobic residues in unfolded proteins, thus the accumulation of unfolded proteins 
would drive the equilibrium of GRP78/BiP binding away from these sensor proteins. 
Perturbations in the ER environment could lead to modification of GRP78/BiP by 
regulating their ATPase and nucleotide exchange activities, causing its release from ER 
stress sensors (Rutkowski and Kaufman, 2004). Furthermore, affinity panning and 
binding assays with random peptide libraries demonstrated that short hydrophobic 
peptides are preferentially bound by GRP78/BiP (Blond-Elguindin et al., 1993).  
In the ADP-bound form GRP78/BiP has high affinity for protein substrates. 
Substrates bound to GRP78/BiP are locked in their conformation and stimulate the 
exchange of ADP with ATP, releasing the substrate from GRP78/BiP, which then 
progresses on its folding pathway (Flynn et al., 1989). Subsequent ATP-hydrolysis 
returns GRP78/BiP into the ADP high affinity state. Moreover, GRP78/BiP forms 
multiprotein complexes which lead to an ER chaperoning network processing the 
unfolded protein substrates (Meunier et al., 2002), that regulates the conformation of its 
substrate binding domain by nucleotide exchange. Both reactions, nucleotide exchanged 
and ATP-hydrolysis, are regulated by co-chaperones, such as the DnaJ-like proteins that 
stimulate the ATPase activity of GRP78/BiP, and the GrpE-like protein BiP-associated 
protein and Sls1p that stimulate the nucleotide exchange reaction (Schroder and 
Kaufman, 2005).  
 
3.1.2. PERK pathway 
 PERK is a Ser/Thr kinase, catalytic domain of which shares substantial homology 
to other kinases of the eukaryotic initiation factor 2α (eIF2α) family (Shi et al., 1998; 
Cunard and Sharma, 2011), and, as IRE1, is a type I transmembrane kinase, sharing 
related luminal domains that are proposed to monitor ER stress via common regulatory 
mechanisms (Schrӧder and Kaufman, 2005). 
 PERK has an ER luminal stress-sensing domain that binds GRP78/BiP and a 
cytosolic kinase domain. When ER stress is sensed, GRP78/BiP dissociates from PERK 
that multimerizes in ER membranes, inducing its autophosphorylation and activating the 
kinase domain (Bertolotti et al., 2000), generating active PERK. Once activated, PERK 
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phosphorylates (at Ser51) and inactivates eIF2α (Heather et al., 1999; Heather et al., 
2000), thereby inhibiting 80S ribosome assembly (Zhang and Kaufman, 2008). This 
results in the inhibition of general protein translation, by shutting off mRNA translation 
and then reducing the protein load on the ER (Figure 6) (Harding et al., 1999; Harding et 
al., 2000). Phosphorylated eIF2α can also activate NF-κB, but still there are controversy 
regarding the precise mechanism involved in this process (Jiang et al., 2003). However, 
certain mRNAs gain a selective advantage for translation under eIF2α phosphorylation, 
activating a signaling pathway called integrated stress response (ISR) (Heather et al., 
2003). In ISR, the phosphorylation of eIF2α is required for the translation of certain 
messenger RNAs that contain regulatory sequences, such as the short open reading 
frames (ORFs) in the 5’-untranslated region of the mRNA, including the mRNA encoding 
activating transcription factor 4 (ATF4) (Yaman et al., 2003; Harding et al., 2003). The 
ATF4 mRNA has two upstream ORFs before the initiation codon that mediates their 
translational regulation (Lu et al., 2004). 
ATF4 is a member of the ATF/CREB (activating transcription factor/cyclic AMP 
response element binding protein) family of basic region-leucine zipper (bZIP) 
transcription factors (Ameri and Harris, 2007). ATF4 can induce the expression of UPR 
target genes, which are involved in amino-acid biosynthesis and transport, protein 
secretion and resistance to oxidative stress (Harding et al., 2003). It also induces the 
expression of growth arrest and DNA damage-inducible protein (GADD34) (Ma and 
Hendershot, 2003), which directly interacts with the catalytic subunit of type 1 protein 
serine/threonine phosphatase (PP1) and activates the ability of PP1 to dephosphorylate 
eIF2α, allowing recovery from the translation repression through a feedback mechanism 
(Novoa et al., 2001).  
However, not all the genes induced by ATF4 are anti-apoptotic. The transcription 
factor C/EBP homologous protein (CHOP) (Ma et al., 2002) and tribbles homolog 3 
(TRB3) (Ohoka et al., 2005), which induction strongly depends on ATF4, are well known 
to promote apoptotic cell death.  
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3.1.3. ATF6 pathway 
 ATF6α, a 90 kDa bZIP (basic region and leucine zipper)-domain-containing 
transcription factor belonging to the CREB (cyclic-AMP-responsive-element-binding 
protein) and ATF family of transcription factors (Haze et al., 1999), is a regulatory 
protein which promotes UPR-inducible gene expression and is activated by proteolysis in 
response to ER stress (Inagi, 2009). This protein is synthesized as inactive precursor, 
tethered to the ER membrane by a trans-membrane segment and has a stress-sensing 
portion that projects into the ER lumen (Ron and Walter, 2007). 
 After dissociating from GRP78/BiP, ATF6 is transported from the ER to the Golgi 
apparatus, packed into a COPII vesicle (Nadanaka e al., 2004), and cleaved by Golgi-
resident proteases, first by site 1 protease (S1P) and then in an intra-membrane region by 
site 2 protease (S2P) to release the functional fragment (bZIP-domain) of ATF6α into the 
cytosol (Shen et al., 2002). This fragment (50 kDa cleaved ATF6α (Eizirik et al., 2008) 
moves to the nucleus where it binds to the ER stress response element (ERSE) 
CCAATN9CCACG (Yoshida et al., 1998) to activate the transcription of target genes 
(Figure 6), which encode ER chaperones, such as GRP78/BiP, GRP94, protein disulfide 
isomerase (PDI) and calreticulin (Okada et al., 2002), and ERAD components 
(Yamamoto et al., 2007). ATF6 also augments X-box binding protein 1 (XBP1) mRNA 
expression, providing more substrate for IRE1-induced generation of XBP1s (spliced 
variant) (Lee et al., 2002), and the CHOP mRNA expression, although no reports have 
linked ATF6 to ER stress-induced apoptosis (Szegezdi et al., 2006). ATF6 is also related 
to OASIS, CREBH, and CREB4, which have tissue-specific effects (Cunard and Sharma, 
2011). 
 
3.1.4. IRE1α pathway 
The IRE1α is a membrane-bound serine/threonine kinase with endonuclease 
activity, owning a novel luminal domain and a cytoplasmic portion that contains a protein 
kinase domain (Cox et al., 1993). After dissociation of GRP78/BiP from the ER luminal 
domain (Oikawa et al., 2009), IRE1α oligomerizes and activates its RNase domain by 
autophosphorylation (Shamu and Walter, 1996). Once activated, IRE1α splices 26-bp 
intron from the mRNA encoding XBP1, generating a spliced variant that functions as a 
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potent transcriptional factor of genes involved in UPR-associated genes, ER homeostasis 
and expansion, and ERAD (Figure 6) (Yoshida et al., 2001; Lee et al., 2003). 
 IRE1α also activates apoptosis signal-regulating kinase (ASK1), c-Jun N-terminal 
kinase (JNK) and NF-κB, which are involved in apoptosis, autophagy and inflammation 
(Urano et al., 2000; Kaneko et al., 2003; Kim et al., 2009).  
 
 
Figure 6. The unfolded protein response. In stress conditions, GRP78/BiP dissociates from the ER stress 
sensors, namely PERK, ATF6 and IRE1, allowing their sequential activation. Activated PERK blocks 
general protein synthesis by phosphorylating eIF2α. This phosphorylation enables translation of ATF4, a 
transcription factor that is translocated to the nucleus and induces the transcription of genes required to 
restore ER homesostasis. ATF6 is activated by limited proteolysis after its translocation from the ER to the 
Golgi apparatus. ATF6 is also a transcription factor that regulates the expression of ER chaperones and 
XBP1. To achieve its active form, XBP1 must undergo MRNA splicing, which is carried out by IRE1. 
Spliced XBP1 protein translocates to the nucleus and controls the transcription of chaperones, as well as 
genes involved in protein degradation. This concerted action aims to restore ER function by blocking 
further buil-up of client proteins, enhancing the folding capacity and initiating degradation of protein 
aggregates. (Image taken from Szegezdi et al., 2006) 
 
3.2. ER stress and apoptosis 
 Although the UPR initially serves as an adaptive response which acts to restore 
ER homeostasis, this physiological response induce an apoptotic response when the ER 
stress crosses a certain persistence and strength. ER stress-induce apoptosis is mediated 
by signaling through PERK, ATF6 and IRE1α, that initiate the activation of downstream 
molecules and activate several pro-apoptotic pathways, including caspase-mediated 
pathway, IRE1α-mediated pathway and CHOP-mediated pathway (Figure 7) (reviewed in 
Inagi, 2009). 
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3.2.1. IRE1α-mediated pathway 
 In response to ER stress, the cytoplasmic domain of activated IRE1α interacts with 
the adaptor protein TNF receptor-associated factor 2 (TRAF2), activating the JNK, via 
interaction with ASK1, which subsequently phosphorylates and activates JNK (Urano et 
al., 2000; Nishitoh et al., 2002), leading to the activation of JNK-mediated apoptotic 
pathway (Figure 7). 
 JNK is known to regulate the anti-apoptotic protein Bcl-2 by its phosphorylation 
and inactivation (Szegezdi et al., 2006), which suppresses the anti-apoptotic activity of 
Bcl-2, inducing apoptosis (Bassik et al., 2004). JNK also phosphorylates BH3-only Bcl-2 
family members, which enhances their pro-apoptotic potential (Szegezdi et al., 2006). 
The IRE1-TRAF2 complex also activates procaspase 12, that also contribute to 
ER stress-mediated apoptosis (Yoneda et al., 2001), and is involved in the activation of 
NF-κB, that can have a pro-apoptotic effect, depending on the cell type and context 
(Kaneko et al., 2003). 
 
3.2.2. Caspase-mediated pathway 
 Some components of the caspase cascade are reported to be involved in ER stress-
induced apoptosis, such as caspases 2, 3, 4, 7, 9 and, in particular, caspase 12 (Cheung et 
al., 2006; Dahmer, 2005; Di Sano et al., 2005; Hitomi et al., 2004) . Caspase 12, which 
resides on the outside of ER membrane, is activated during ER stress by calpain, which 
cleaves the ER-resident procaspase-12 to caspase-12, initiating caspase-dependent 
apoptosis (Figure 7) (Tan et al., 2006). Caspase-12 triggers the activation of caspases 9, 
which in turns activate caspase-3, in a cytochrome c and Apaf-1-independent manner 
(Morishima et al., 2002; Rao et al., 2002), leading to cell death. ER stress also causes the 
translocation of cytosolic caspase-7 to ER surface, which is also required for caspase-12 
activation (Rao et al., 2002). 
 In addition, BAX-BAK pathway also activates caspase-12-mediated apoptosis 
(Inagi, 2009). BAX and BAK are present at the mitochondrial and ER membrane, and 
under ER stress conditions cause the release of Ca
2+
 from ER increasing the cytosolic 
Ca
2+
 concentration. This increased cytosolic Ca
2+
 concentration activates calpain present 
in the cytosol, which then leads to caspase-12 activation (Scorrano et al., 2003; Oakes et 
al., 2005). 
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3.2.3. CHOP-mediated pathway 
 CHOP, also known as growth arrest and DNA damage-inducible protein 153 
(GADD153), is a bZIP transcription factor, induced through the ATF6 and PERK UPR 
pathways (Figure 7) (Szegezdi et al., 2006), playing an important role in ER stress-
mediated apoptosis (Nishitoh, 2012). However, the precise mechanism how CHOP 
mediates ER stress-induced apoptosis remains controversial (Malhotra and Kaufman, 
2007; Nishitoh, 2012). 
 One of the mechanisms that is considered to contribute to CHOP-mediated 
apoptosis is the transcription of several genes involved in apoptosis, such as GADD34, 
ER oxidoreductin 1 (ERO1), death receptor 5 (DR5), TRB3, carbonic anhydrase VI 
(Yamaguchi and Wang, 2004; Ohoka et al., 2005; Marciniak et al., 2004; Malhotra and 
Kaufman, 2007), and the induction of the BH3-only pro-apoptotic proteins, such as Bim 
(Puthalakath et al., 2007). The translocation of BAX from the cytosol to the mitochondria 
(Gotoh et al., 2004), the down-regulation of anti-apoptotic Bcl-2 expression and 
perturbation of the cellular redox state by depletion of cellular glutathione (McCullough 
et al., 2000), may also contribute to CHOP-mediated apoptosis. 
 ER stress-associated apoptosis induced by CHOP is dependent of the duration and 
degree of ER stress. Severe ER stress preferentially induces pro-apoptotic CHOP 
expression, while chronic exposure to a mild stress can lead to attenuation of CHOP 
expression, by degradation of CHOP mRNA and CHOP protein (Rutkowski et al., 2006). 
 
 
Figure 7. ER stress induced apoptosis. Three main pathways involved: CHOP-mediated pathway, 
Caspase-mediated pathway and IRE1 α -mediated pathway. (Adapted from Inagi, 2009) 
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3.3. ER stress and inflammation 
 Accumulating evidences suggests ER stress plays an important role in the 
pathogenesis of diabetes. ER may also link inflammation in T2DM. In fact, ER stress 
attenuation decreases the expression of proinflammatory cytokines in diabetic kidney (Qi 
et al., 2010). The signaling pathways in the UPR and inflammation are connected through 
diverse mechanism, including the production of ROS and the activation of NF-κB and 
JNK.  
 ROS are important mediators of inflammation (Naik and Dixi, 2011), and 
generation and accumulation of intracellular ROS (state referred as oxidative stress) have 
been associated to the ER stress. The correct folding of proteins requires oxidizing 
conditions for the formation of intramolecular and intermolecular disulphide bonds. The 
oxidative protein folding is driven by a protein relay involving ERO1 and PDI (Tu and 
Weissman, 2004). PDI has been known to aid the formation of disulphide bonds, as it 
directly accepts electrons from protein-folding substrates, resulting in the oxidation of 
cysteine residues and the formation of disulphide bonds. Then, ERO1 operates in 
association with the flavin adenine dinucleotide (FAD) to transfer electrons from PDI to 
molecular oxygen (O2), resulting in the production of ROS (Zhang and Kaufman, 2008). 
Given that the UPR increases the protein-folding load in the ER, an accumulation of ROS 
might initiate an inflammatory response.  
  Moreover, NF-κB, a key transcriptional regulator of genes involved in the 
inflammatory response, is activated by ER stress. In response to ER stress, the UPR can 
directly promote NF-κB activation through a PERK-eIF2α and IRE1-TRAF2 pathways, 
by translational attenuation and degradation of IκB, respectively (Zhang and Kaufman, 
2008). The IRE1α-TRAF2 pathway can also lead to the activation of JNK, and activated 
JNK induces the expression of inflammatory genes by the phosphorylation of the 
transcription factor AP1 (Davis et al., 2000). 
 Recent findings suggest that CHOP is a key molecule not only in apoptosis but 
also in inflammatory response. UPR-induced CHOP expression is implicated in the 
induction of caspase-11 that plays an important role in the processing of pro-IL-1β 
through caspase-1 activation (Endo et al., 2006). 
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3.4. ER stress and diabetes 
 The ER stress response is implicated in a number of pathogenesis, including 
neurodegenerative diseases, atherosclerosis and metabolic diseases, such as diabetes 
(Malhotra and Kaufman, 2007). Accumulating evidence suggests that ER stress 
contribute to pancreatic β-cells loss and insulin resistance (Araki et al., 2003; Kaneto et 
al., 2006; Song et al., 2008). Apoptosis in β-cells plays an important role in development 
of diabetes, both type 1 and 2 (Mathis et al., 2001; Butler et al., 2003), and these cells 
have a highly developed and active ER, showing a high expression of ER stress 
transducers proteins such as Ire1α, PERK and GRP78/BiP (Eizirik et al., 2008; Malhotra 
and Kaufman, 2007). This may reflect the fact that β-cells are very susceptible to ER 
stress, and also highly engaged in protein secretion (Araki et al., 2003). 
In T1DM, β-cell loss is linked to nitric oxide (NO) production by inflammatory 
cytokines, such as IL-1β, TNF and IFN-γ (Darville and Eizirik, 1998; Thomas et al., 
2002). Oyodomari et al (2001) demonstrated that NO-induced apoptosis in β-cells is 
mediated by the ER stress pathway through induction of the ER stress-associated 
apoptosis factor CHOP. Treatment of mouse insulinoma cell line MIN-6 with NO donor 
SNAP (S-nitroso-Nacetyl-D, L-penicillamine) suggest that NO depletes ER Ca
2+
 stores 
(Oyadomari et al., 2001). A severe Ca
2+ 
ER depletion leads to disturbance of ER function 
and impairment in the quality of ER protein folding and assembly, causing ER stress and 
downstream CHOP-induced apoptosis (Araki et al., 2003; Cardozo et al., 2005; Eizirik et 
al., 2008). 
 In T2DM, it is known that a high-fat diet and/or obesity contribute to the 
development of this pathology, as a consequence of lipotoxicity/glucotoxicity and insulin 
resistance. It has been shown that free fatty acids (FFAs) (lipotoxicity) as palmitate, and 
high glucose levels (glucotoxicity) induced the activation of ER stress response in β-cells, 
leading to β-cell apoptosis (Karaskov et al., 2006; Cnop et al., 2007; Elouil et al., 2007; 
Lawrence et al., 2007). Palmitate leads to phosphorylation of PERK and eIF2α, inhibition 
of protein synthesis and induction of ATF4 and CHOP, causing β-cell apoptosis (Cnop et 
al., 2007). High glucose induces both the expression of CHOP and ER chaperones (Elouil 
et al., 2007; Lawrence et al., 2007). On the other hand, glucose is known to stimulate 
insulin biosynthesis (Itoh and Okamoto, 1980). Thus high glucose levels induce increased 
demand of insulin that result in increased proinsulin biosynthesis exceeding the folding 
CHAPTER 1 – Introduction and Aims 
26 
 
capacity of ER, leading to ER overload and ER stress. This, in turn, causes β-cell 
dysfunction and apoptosis (Kim et al., 2012). 
 The importance of the UPR in diabetes is not restricted to β-cell function but is 
also involved in insulin resistance. ER stress has been proposed as one of the molecular 
mechanism linking obesity with peripheral insulin resistance, through alterations on 
insulin signaling (Ozcan et al., 2004). ER stress suppresses insulin receptor signaling 
through activation of the protein kinase JNK. JNK phosphorylation of IRS-1 on Ser307 
reduces insulin receptor-stimulated tyrosine phosphorylation, decreasing insulin signaling 
(Ozcan et al., 2006; Hirosumi et al., 2002). Indeed, Ozcan et al. (2004) demonstrated that, 
in obese mice, JNK activity increases dramatically. 
 Additionally, altered metabolic conditions associated with diabetes, such as ROS 
production, FFAs and hyperglycaemia, can lead to UPR response and contribute for the 
development of diabetic complications (King and Loeken, 2004; Kaneto et al., 2005), 
including diabetic nephropathy (Lindenmeyer et al., 2008). 
 
3.4.1. ER stress and diabetic nephropathy 
There is increasing evidence indicating that the ER stress has an important role in 
renal injury onset in diabetes (Liu et al., 2008; Inagi et al., 2005; Inagi et al., 2010; Lim et 
al., 2010; Shao et al., 2013). Renal cells have a well-developed ER, turning them 
particularly sensitive to perturbations in ER function. Indeed, studies in proximal tubular 
cells revealed upregulation of GRP78/BiP by albumin overload (Ohse et al., 2006). 
Recent studies have been indicated that ER stress response is activated in T1DM 
kidneys, and can be responsible for renal cells apoptosis mediated by activation of CHOP, 
JNK and caspase-12 proteins (Liu et al., 2008). Renal proximal tubular cells apoptosis is 
also linked to ER stress response activation (Lim et al., 2010). In addition, ROS seem to 
play a crucial role in podocyte injury by CHOP protein upregulation (Bek et al., 2006).  
 
During recent years, accumulating evidences suggest the relevance of ER stress in 
the development and pathogenesis of DN. Therefore, it is crucial to better understand the 
role of ER stress in renal lesions due to diabetes.  
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4. Diabetes therapy – dipeptidyl peptidase-IV inhibitors 
A new class of oral anti-diabetic agents, the dipeptidyl peptidase-IV (DPP-IV) 
inhibitors or gliptins, such as sitagliptin, has increasingly gained emphasis in the 
therapeutic managing of T2DM patients. These inhibitors are mainly responsible for 
lowering blood glucose levels by potentiating incretins action, stimulating insulin 
secretion and inhibiting glucagon activity, in response to chronic hyperglycaemia.  
 
4.1. Incretins 
 Incretins are peptide hormones that are involved in the physiologic regulation of 
glucose homeostasis, as exemplified by glucagon-like peptide-1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP) (Barnett, 2006; Drucker, 2006). Incretin 
hormones are secreted from the gastrointestinal tract after food intake, in a nutrient-
dependent manner, and stimulate glucose-dependent insulin secretion. The insulin 
secretory response of incretins is called incretin effect, and accounts for at least 50% of 
total insulin secreted after oral glucose. Therefore, incretin hormones are insulinotropic 
(Kim and Egan, 2008). 
 The first incretin hormone described was GIP. GIP is a 42 amino acid peptide 
produced predominantly in duodenal K cells in the proximal small intestine (duodenum 
and jejunum) (Buchan et al., 1978; Takeda et al., 1987). The predominant stimulus for 
GIP secretion is nutrient intake, namely absorbable carbohydrates and lipids. Circulating 
levels of GIP are therefore greatly increased in response to food ingestion (Holst and 
Gromada, 2004). In addition to being insulinotropic, GIP also regulates fat metabolism in 
adipocytes, including insulin-stimulated incorporation of fatty acids into triglycerides. 
Additionally, it stimulates lipoprotein lipase activity, modulates fatty acid synthesis, 
promotes β-cell proliferation and cell survival (Drucker, 2003).  
GLP-1 was the second incretin hormone identified. GLP-1 is produced in 
enteroendocrine L-cells in the distal small bowel and colon, where is secreted into the 
bloodstream in response to nutrient ingestion (Jang et al., 2007). Like GIP, plasma levels 
of GLP-1 also rise rapidly minutes after food intake. GLP-1 is thought to increase insulin 
biosynthesis trough induction of Pdx-1 transcription, leading to enhanced insulin gene 
expression (Wang et al., 1999). In addition to its insulinotropic effects (Nauck et al., 
1993), GLP-1 also inhibits gastric emptying which decreases food intake (Meier et al., 
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2003), suppresses the elevated glucagon secretion (Komatsu et al., 1989) and slows the 
rate of endogenous glucose production (Prigeon et al., 2003). It has also been shown that 
GLP-1 preserves or enhances β-cells function as a result of β-cell proliferation and 
inhibition of apoptosis (Farilla et al., 2002). GLP-1 appears to be responsible for the 
majority of the incretin effect on pancreatic β-cell function and is responsible for a 
substantial part of the insulin response to oral glucose. Therefore, it has become a favored 
potential therapeutic target. 
GIP and GLP-1 achieve their insulinotropic effects by binding to their specific 
receptors, which are coupled to G protein (Figure 8). GIP receptor (GIPR) is expressed in 
pancreatic islets and also in the gut, adipose tissue, heart and brain (Holst and Gromada, 
2004; Drucker, 2006). On the other hand, GLP-1 receptor (GLP-1R) is widely expressed 
in the kidney, lung, heart, and also in central nervous system and pancreatic islets, mainly 
in β-cells (Drucker, 2006). Binding of GIP and GLP-1 to the receptors causes activation 
of adenylate cyclase which results in the formation of intracellular cyclic adenosine 
monophosphate (cAMP), leading to PKA and cAMP-regulated guanine nucleotide ex-
change factor II (cAMP-GEFII) activation. This leads to several events, including altered 
ion channel activity, increased intracellular calcium concentration and enhanced 
exocytosis of insulin-containing granules (Figure 8) (Holz, 2004). Furthermore, GLP-1R 
activation also leads to induction of insulin gene transcription (Drucker et al., 1987) and 
increased pancreatic insulin biosynthesis (Hosokawa et al., 1996). 
The incretin effect is restricted by GIP and GLP-1 short half-life, that is about 1 to 
2 minutes in rodents (Kieffer et al., 1995), 7 minutes in healthy humans and 5 minutes in 
T2DM patients for exogenous GIP (Deacon et al.,, 2000), and about 2 minutes in rodents 
and humans for exogenous GLP-1 (Deacon et al., 1995). The incretin degradation is 
remarkably rapid due to its inactivation by DPP-IV.  
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Figure 8. GLP-1R and GIPR activation, and main molecular events during incretin-induced insulin 
secretion from β-cell. Binding of GLP-1 and GIP to their receptors couples to activation of adenylate 
cyclase, and intracellular cAMP levels are elevated, leading to activation of PKA and cAMP-GEFII, which 
leads to elevation of intracellular Ca
2+
 levels via a depolarization of plasma membrane by inhibition of KATP 
and KV channels, after ATP generation from glucose and consequent opening of voltage-gate L-type Ca
2+
-
channel. Intracellular Ca
2+
 levels are further increased via stimulation of IP3R and RyR on the ER. In 
addition, L-type Ca
2+
 channels are phosphorylated by PKA, resulting in an increase of their open 
probability and thus facilitation of enhanced Ca
2+
 influx. The changes in intracellular Ca
2+
 concentrations 
lead to fusion of insulin-containing vesicles to the plasma membrane and subsequent rapid exocytosis of 
insulin from β-cells. The exocytosis of insulin-containing vesicles is also potentiated by increased cAMP 
levels, due to the ability of cAMP to accelerate granule mobilization, resulting in an increased size of the 
pools of granules that are immediately available for release. (Image taken from Holst and Gromada, 2004) 
 
4.2. Dipeptidyl peptidase-IV (DPP-IV) 
DPP-IV is the primary enzyme responsible for inactivating both GIP and GLP-1, 
by cleavage of the penultimate alanine residue in N-terminal of full-length (Mentlein et 
al., 1993), which converts them to bioinactive metabolites. DPP-IV, also known as CD26, 
is a membrane-associated peptidase of 766 amino acids that is widely distributed in 
numerous tissues and cells, such as lymphocytes, endothelial cells, gut, liver, pancreas 
and kidney, as well as being present in soluble form in the circulation in plasma (Pauly et 
al., 1996; Barnett, 2006; Kim and Egan, 2008; Kirino et al., 2009). DPP-IV has a serine 
exopeptidase activity that cleaves X-proline dipeptides from the N-terminus of 
polypeptides, and the substrates of this enzyme are proline- or alanine-containing 
peptides, which include numerous neuropeptides, hormones and chemokines (Baggio and 
Drucker, 2007). Therefore, DPP-IV inhibition has a range of possible pleiotropic effects, 
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well beyond GLP-1 modulation, that may or may not provide additional positive effects 
for diabetes treatment. 
Insight into the role of DPP-IV in the control of incretin biology has been derived 
from several studies with inactivating mutations in the DPP-IV gene and from the results 
of experiments using inhibitors of DPP-IV activity, which potentiates endogenous GLP-1 
and GIP action by reduction of incretin degradation. In DPP-IV knockout mice, it was 
observed increased levels of GIP and GLP-1, as well as an improvement in glucose 
tolerance and enhanced insulin secretion (Marguet et al., 2000). Additionally, studies 
using DPP-IV inhibitors to treat rodents with experimental diabetes also showed 
significant improvements in glucose tolerance, preservation of GLP-1 levels and 
increased levels of plasma insulin after oral glucose (Baggio and Drucker, 2007). 
Moreover, it has been shown that treatment with DPP-IV inhibitors in animal models of 
type 1 and 2 diabetes preserves islet function and increases pancreatic insulin content, 
through increasing proliferation, neogenesis and apoptosis resistance of β-cells (Reimer et 
al., 2002; Popisilik et al., 2003). 
Clinical trials in type 2 diabetic patients demonstrated that the treatment with 
DPP-IV inhibitors improve postprandial and fasting glycaemic control, in association 
with increased GLP-1 levels and reduced glucagon levels (Ahren et al., 2002). 
Complementary studies also demonstrated that DPP-IV inhibitors increase the insulin 
secretory rate in type 2 diabetic patients, which suggests an improvement in β-cell 
function (Mari et al., 2005). 
 
4.3. Sitagliptin 
Many DPP-IV inhibitors have entered clinical trials in diabetic patients, namely 
sitagliptin, the first one, vidaglitin, saxagliptin and others that were further developed 
(Barnett, 2006). Sitagliptin is an oral, once-daily, potent and highly selective DPP-IV 
inhibitor for treatment of T2DM, improving fasting and postprandial glycaemia and 
deceasing glycosylated hemoglobin (HbA1c) levels (Herman et al., 2007). Sitagliptin is a 
well-tolerated anti-diabetic drug, without weight changes and with low propensity to 
cause hypoglycaemia (Drucker and Nauck, 2006).  
The DPP-IV enzyme contains two glutamate residues (Glu
205
 and Glu
206
) highly 
conserved, that are essential for its enzymatic activity (Abbott et al., 1999), and has been 
demonstrated experimentally that the amino groups contained within the DPP-IV 
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inhibitor sitagliptin interact with these two glutamate residues (Biftu et al., 2007), which 
inhibits the enzymatic activity of DPP-IV. 
Sitagliptin is a small non-peptide-based active molecule with 523.32 Da of 
molecular weight, corresponding chemically 7-[(3R)-3-amino-1-oxo-4-(2,4,5-
trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluormethyl)-1,2,4-triazolo[4,3-a]pyrazine 
phosphate (1:1)monohydrate (Figure 9). Sitagliptin was approved by INFARMED for the 
treatment of T2DM in Portugal in November 2007.  
 
 
Figure 9. Chemical struture of Sitagliptin (Adaptef from Barnett, 2006) 
 
Oral sitagliptin is rapidly absorbed and achieves peak plasma levels in 1 to 6 
hours, and the administration can be in the presence or absence of food. Its half-life is 8 to 
14 hours and its bioavailability is approximately 87% (Kim and Egan, 2008). 
Approximately 80% of the dose is excreted unchanged by the kidney and a small amount 
(15%) is metabolized in the liver (Bergman et al., 2007; Kim and Egan, 2008). The 
recommended dose is 100 mg daily, which inhibits DPP-IV activity at least 80% over a 
24 hours period (Aschner et al., 2006). Sitagliptin was evaluated as monotherapy or in 
combination with other anti-diabetic drugs, such as metformin, showing that sitagliptin 
alone significantly reduces HbA1C levels about 0.79% in type 2 diabetic patients, with 
100 mg once daily treatment for 24 weeks (Aschner et al., 2006). Several clinical trials in 
patients with T2DM showed that sitagliptin was well tolerated and significantly improves 
glycaemic levels, by lowering blood glucose and HbA1C levels (Ahren et al., 2002; Kim 
et al., 2005; Aschner et al., 2006; Raz et al., 2006; Nonaka et al., 2007). 
Recent studies demonstrated that sitagliptin have high selectivity for DPP-IV 
(IC50: 18 nM) (Weber et al., 2004), which is required for an acceptable safety and 
tolerability treatment. At least two dipeptidyl peptidases, such as dipeptidyl peptidases 
VIII (DPP-VIII) and dipeptidyl peptidases IX (DPP-IX), are structurally closely related to 
DPP-IV, but sitagliptin have low affinity for these peptidases, with IC50: 48000 nM for 
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DPP-VIII and IC50: >100000 nM for DPP-IX (Kim et al., 2005). Acute toxicity in animal 
models was reported with DPP-VIII and DPP-IX inhibition (Lankas et al., 2005); by that, 
the low selectivity of sitagliptin for DPP-VIII and DPP-IX enhances the safety of the 
treatment. 
 
Given that sitagliptin is orally bioavailable might offer greater benefits compared 
with injectable agents (e.g. insulin) in terms of patient compliance. Moreover, sitagliptin 
significantly improves glycaemic levels, promotes β-cell survival and enhances insulin 
secretion, as well as offers low risk of hypoglycaemia and no weight gain. All these 
potential advantages enhance the therapeutic benefits of sitagliptin when related to other 
anti-diabetic drugs, turning it a promising therapeutic intervention for T2DM treatment, 
not only by it direct effects on glycaemic control, but also by the pleiotropic effects of 
incretins (Figure 10). 
 
 
Figure 10. Pleiotropic effects of GLP-1. Schema outlining the incretin downstream signal transduction 
pathways in a β-cell. GLP-1R activation (and GIPR activation to some extent) recruits signaling mechanism 
that considerably overlap, leading to promotion of β-cell proliferation and prevention of β-cell apoptosis. 
Dashed line indicates mechanism that is not fully delineated. (Image taken from Kim and Egan, 2008) 
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5. Aims of this thesis 
 Several authors have been exploiting the cytoprotective actions of DPP-IV 
inhibitors in distinct organs and conditions, including pancreas, retina and heart (Mu et 
al., 2006; Gonçalves et al., 2010; Read et al., 2010). However, until now, few studies 
have addresses the putative beneficial impact of these agents, including sitagliptin, on DN 
(Vaghasiya et al., 2010; Liu et al., 2011; Mega et al., 2011).  
In addition, the impact of sitagliptin therapy on ER stress, inflammation and 
apoptosis underlying DN development remains relatively unexploited. Therefore, the 
general goal of this study is to evaluate the efficacy of sitagliptin, a DPP-IV inhibitor, in 
preventing the deleterious effects of diabetes on the kidney of Zucker Diabetic Fatty 
(ZDF) rats. 
 
To accomplish the main purpose, specific approaches have been devised as 
follows: 
 
 Characterization of glycaemic profile of non-diabetic ZDF (+/+) and diabetic ZDF 
(fa/fa) non-treated and treated with sitagliptin, by measuring blood glucose, 
HbA1c and insulin levels. 
 Assessment of the incretin signaling pathway: DPP-IV/CD26, GLP-1 and GLP-1R 
protein levels in the kidney will be determined. 
 Evaluation of Akt survival pathway as an indicator of ECM expansion and 
mesangial hypertrophy in the kidney. 
 Analysis of the inflammatory state: proinflammatory cytokines TNF and IL-1β 
distribution in kidney sections will be evaluated. 
 Evaluation of the apoptotic state: BAX/Bcl-2 ratio and pro-apoptotic Bid protein 
levels in the kidney will be determined. 
 Assessment of the ER stress response: CHOP, GRP78/BiP and ATF4 protein 
levels in the kidney will be analyzed. 
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1. Animal model and groups 
In this study, we used a rodent model of obese T2DM, the Zucker Diabetic Fatty 
(ZDF) rats, which develop obesity, hyperlipidaemia, fasting hyperglycaemia, 
hyperinsulinaemia and insulin resistance (Peterson et al., 1990). 
Obese ZDF rats (ZDF, fa/fa) and non-obese non-diabetic controls (ZDF, +/+) with 
6 weeks age were obtained from Charles River Laboratories (Barcelona, Spain), and 
before starting the study, there was 2 weeks of acclimatization. Rats were housed under 
controlled temperature (23±1ºC) and relative humidity (60%), and a 12-h light-12-h dark 
cycle. The animals were fed distilled water ad libitum and rodent maintenance chow (A-
04 Panlab, Barcelona, Spain) containing 15.4% of protein and 2.9% of lipids. In this 
study, diabetic ZDF (fa/fa) and non-diabetic ZDF (+/+) rats with 20 weeks age were used. 
All procedures involving animals were performed according to the National and 
European Communities Council Directives on Animal Care. 
 
At 20 weeks of age, ZDF (fa/fa) rats were divided into two groups (n=6-8 rats per 
group) and were orally treated during 6 weeks with vehicle (orange juice) or sitagliptin 
(Januvia®, MSD, Portugal) 10 mg/kg/day. Therefore, we had three groups of animals: (1) 
control ZDF (+/+) group treated with vehicle; (2) diabetic ZDF (fa/fa) group with vehicle 
treatment and (3) diabetic ZDF (fa/fa) group under sitagliptin therapy. 
The body weight of each animal was recorded weekly during the experimental 
period, using an analytical balance (KERN CB 6 K1, Alemanha).  
 
1.1. Sample collection 
At the end of the treatment, rats were anaesthetized (2 mg/kg intraperitoneal 
cocktail of a 2:1 50 mg/ml ketamine solution in 2.5% chlorpromazine) and blood from the 
jugular vein was collected. After that, rats were sacrificed and the kidneys immediately 
removed and carefully cleaned of adherent fat and connective tissue. The kidneys were 
embedded in OCT tissue embedding matrix (Thermo Scientific, Waltham, MA, USA) at -
50ºC, for immunohistochemistry and fluorescence microscopy studies, or divided in 
sections, that were frozen in liquid nitrogen and then stored at -80ºC, for immunoblot 
analysis. 
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1.2. Biochemical data 
Serum glucose levels were measured through blood samples from the tail vein 
using a glucose oxidase commercial kit (Sigma, St. Louis, Mo, USA) and HbA1c levels 
were measured in total blood by DCA 2000+ Analyser (Bayer Diagnostics, Barcelona, 
Spain).  
 
2. Protein extraction from rat kidney 
Kidney sections were weighted, cut into small pieces and homogenized by 
mechanical dissociation using a Potter-Elvehjem, at 4ºC, in 5 volumes of RIPA lysis 
buffer (150 mM NaCl, 50 mM Tris (pH 7.5), 5 mM ethylene glycol tetraacetic acid 
(EGTA), 1% (v/v) Triton X-100 (Tx-100), 0.5% (m/v) sodium deoxycholate (DOC) and 
0.1% (m/v) sodium dodecyl sulfate (SDS), supplemented with 2 mM 
phenylmethylsulfonyl fluoride (PMSF), 2 mM iodoacetamide (IAD), 30 mM NaF, 1 mM 
sodium orthovanadate and 1x protease inhibitor cocktail (Roche, Indianapolis, IN, USA)). 
After incubation on ice for 1h, the lysates were sonicated and then centrifuged at 
16,000×g, for 15 min, at 4ºC. 
After centrifugation, the resulting supernatant fraction (corresponding to total 
extract) was collected and protein concentration was determined using the bicinchoninic 
acid assay (Pierce, Rockfor, IL, USA). Sample were then denatured with 6x Laemmli 
buffer (350 mM Tris-HCl (pH 6.8), 30% (m/v) glycerol, 10% (m/v) SDS, 600 mM DL-
dithiothreitol (DTT) and 0.012% (m/v) bromophenol blue) for 1h at 37ºC. 
 
3. Subcellular fractionation by sucrose gradient 
Rat kidney subcellular fractions were prepared as previously described by 
Mosevitsky and Silicheva (2009). Kidney sections were weighted, cut into small pieces 
and homogenized by mechanical dissociation using a Potter-Elvehjem, at 4ºC, in 4 
volumes of hypotonic buffer A (20 mM Tris-HCl (pH 7.4), 4 mM NaCl and 1 mM 
ethylene diamine tetraacetic acid (EDTA), supplemented with 2 mM PMSF, 30 mM NaF, 
2 mM IAD, 1 mM sodium orthovanadate and 1x protease inhibitor cocktail (Roche, 
Indianapolis, IN, USA) with 10% (m/v) sucrose. The homogenate obtained was filtered 
with a nylon mesh (250 μm) and the filtrate was centrifuged at 3,000×g for 15 min, at 
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4ºC. The supernatant (cytoplasmic fraction) was collected and then pellet was 
resuspended in hypotonic buffer A (2.4:1) with 10% sucrose and 0.5% (v/v) Triton X-
100. After incubation for 5 min in an ice bath, the suspension was layered on the top of 
40% (m/v) sucrose in hypotonic buffer B (20 mM tris-HCl (pH 7.4), 4 mM NaCl and 1 
mM EDTA, supplemented with 2 mM PMSF and 2 mM IAD and centrifuged at 7000 g 
for 20 min, at 4ºC. The pellet was gently resuspended in hypotonic buffer A (2.4:1) with 
10% sucrose and 0.5% (v/v) Triton X-100, and the centrifugation was repeated. The 
dense white pellet (cell nuclei) obtained after centrifugation was finally resuspended in 
RIPA lysis buffer (2.4:1) (150 mM NaCl, 50 mM Tris (pH 7.5), 5 mM EGTA, 1% (v/v) 
Triton X-100 (Tx-100), 0.5% (m/v) sodium deoxycholate and 0.1% (m/v) SDS, 
supplemented with 2 mM PMSF, 2 mM IAD, 30 mM NaF, 1 mM sodium orthovanadate 
and 1x protease inhibitor cocktail (Roche, Indianapolis, IN, USA)). After incubation on 
ice for 1h, the lysates were sonicated and then centrifuged at 14.000g for 10 min, at 4ºC, 
and the supernatant was collected (nuclei fraction).  
Protein concentration of cytoplasmic and nuclei fractions were determined using 
the bicinchoninic acid assay (Pierce, Rockfor, IL, USA), and then were denatured as 
previous described. 
 
4. Polyacrylamide gel electrophoresis and immunodetection 
(Western blotting)  
For the western blot analysis, 40 to 80 µg of protein were loaded per lane and 
separated by electrophoresis on SDS-12% or SDS-10% polyacrylamide gel in buffer 25 
mM Tris-HCl (pH 8.0-8.5) containing 192 mM glycine and 0.1% (m/v) SDS, at 160 V. 
After electrophoresis, protein were electro-transferred to polyvinylidene difluoride 
(PVDF) (Immobilon
®
-P PVDF transfer membranes 0,45 µm, Millipore) or nitrocellulose 
(Trans-Blot
®
Turbo
™ 
Midi Nitrocellulose Transfer Pack 0.20 µm membranes, Bio-Rad 
Life Science) membranes. Western blot transfer was performed using 25 mM Tris-HCl 
(pH 8.0-8.5) containing 192 mM glycine, 20% (v/v) methanol and 0.005% (m/v) SDS, for 
1h 30min at 260 mA, at 4ºC. After transfer, membranes were blocked with 5% (m/v) non-
fat milk in Tris-buffered saline (TBS: 20 mM Tris (pH 7.6) and 150 mM NaCl, 
containing 0.1% (v/v) Tween-20 (TBS-T)), for 1h with agitation, at room temperature. 
Membranes were incubated with primary antibodies (Table 1), diluted in TBS-T 
supplemented with 5% non-fat milk or 5% (m/v) bovine serum albumin (BSA), overnight 
CHAPTER 2 – Material and Methods 
40 
 
at 4ºC. Membranes were washed three times with TBS-T for 30 min and then incubated 
with adequate horseradish peroxidase (HRP) conjugated secondary antibodies (Table 1) 
with agitation for 1h, at room temperature. After secondary antibody incubation, 
membranes were washed again for 30 min with TBS-T and reprobed with enhanced 
chemiluminescence (ECL) reagent (Bio-Rad Life Science). To confirm equal protein 
loading and sample transfer, blots were reprobed with mouse anti- β-actin, rabbit anti-
Lamin B1 or goat anti-GAPDH antibodies. 
Immunoreactive bands were revealed by scanning blots using a VersaDoc (Bio-
Rad Life Science) imaging system. Densitometric analyses were performed using the 
ImageJ 1.42n software.  
 
Table 1. Primary and secondary antibodies used for Western Blotting analysis. 
Antibody Dilution Company 
Mouse monoclonal antibody anti-Bcl-2 1:200 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, 
USA) 
Rabbit polyclonal antibody anti-Bax 1:200 Santa Cruz Biotechnology, Inc.  
Rabbit polyclonal antibody anti-Bid 1:500 Chemicon (CA, USA) 
Rabbit polyclonal antibody anti-CD26 1:4000 Abcam (Cambridge, UK) 
Mouse monoclonal antibody anti-GLP-1 1:1000 Abcam  
Mouse anti-GRP78/BiP 1:500 
BD Transduction Laboratories (San Jose, CA, 
USA) 
Goat polyclonal antibody anti-ATF4 1:166.7 Sigma-Aldrich Co. (St. Louis, MO, USA) 
Mouse monoclonal antibody anti-CHOP 1:1000 Cell Signaling (Danvers, MA, USA.) 
Rabbit monoclonal antibody anti-P-Akt 1:2000 Cell Signaling 
Rabbit polyclonal antibody anti-Lamin B1 1:4000 Abcam 
Goat polyclonal antibody anti-GAPDH 1:10000 Sicgen (Coimbra, Portugal) 
Mouse monoclonal antibody anti-β-Actin 1:10000 Sigma-Aldrich Co. 
HRP secondary anti-mouse 1:10000 Bio-Rad (Hercules, CA, USA) 
HRP secondary anti-rabbit 1:10000 Bio-Rad 
HRP secondary anti-goat 1:10000 Bio-Rad 
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5. Immunohistochemistry 
Cross sections of rat kidney (6 μm) were cut in a cryostat (Leica CM3050S, 
Nussloch, Germany). Transverse sections of rat kidney were fixed with cold acetone for 
10 min, and then washed, with phosphate-buffered saline (PBS: 137 mM NaCl, 27 mM 
KCl, 81 mM Na2HPO4, 15 mM KH2PO4, pH 7.3) (3×5 min). After washing, sections 
were permeabilized for 30 min with 0.25% (v/v) Triton X-100 in PBS and blocked for 40 
min with 10% (v/v) normal goat serum or with 5% (m/v) BSA, prior to incubation with 
the primary antibodies (Table 2) diluted in PBS with 0.25% Triton X-100, overnight at 
4ºC. Samples were washed with washing buffer (3×5 min). Sections were incubated with 
the secondary fluorescent antibodies (Table 2) and 1μg/ml 4’,6-diamidino-2-phenylindole 
(DAPI) for 1h at room temperature in a humidified chamber in the dark. After incubation, 
sections were washed with PBS three times of 5 min each, and the slides were mounted 
using the Glycergel mouting medium (Dako, Carpinteria, CA, USA) and sealed with nail 
polish. The samples were stored at 4ºC until acquisition of images in the confocal 
fluorescence microscope (LSM 710, Carl Zeiss, Gottingen, Germany). For a negative 
experiment, the primary antibody was omitted. 
 
Table 2. Primary and secondary antibodies used in the immunofluorescence assays.  
Antibody Dilution Company 
Rabbit polyclonal antibody anti-Bax 1:50 Santa Cruz Biotechnology, Inc.  
Rabbit polyclonal antibody anti-CD26 1:150 Abcam  
Rabbit polyclonal antibody anti-GLP-1R 1:200 Abcam  
Mouse monoclonal antibody anti-GLP-1 1:250 Abcam  
Mouse monoclonal antibody anti-CHOP 1:150 Cell Signaling  
Goat polyclonal antibody anti-IL-1β 1:100 R&D Systems (Minneapolis, MN, USA.) 
Rabbit polyclonal antibody anti-TNF 1:500 R&D Systems  
Alexa Fluor 568 goat anti-mouse 1:200 Molecular Probes Inc. (OR, USA) 
Alexa Fluor 488 goat anti-rabbit 1:300 Molecular Probes Inc.  
Alexa Fluor 594 donkey anti-goat 1:100 Molecular Probes Inc. 
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6. Statistical analysis 
Results were statistically analyzed using GraphPad Prism (GraphPad Prism 5.0 
software, La Jolla, CA, USA), and expressed as mean ± standard errors of the mean 
(SEM). The comparison of values between groups was performed by using analysis of 
variance (ANOVA) followed by Bonferroni´s Post-hoc test. Values of p<0.05 were 
considered statistically significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
RESULTS 
 
 
  
 
 
 
 
CHAPTER 3 – Results 
45 
 
1. Sitagliptin prevents the weight loss and decreases glucose 
and HbA1c blood levels in the diabetic animals  
 Rodent models of T2DM are frequently used to clarify the mechanisms 
responsible for the pathophysiology of diabetes evolution, as well as its complications, 
such as DN. The T2DM animal model used in this study was the Zucker Diabetic Fatty 
(ZDF) rat, which presents a mutation in the gene encoding the leptin receptor (fa/fa) 
resulting in obesity, insulin resistance, reduced glucose tolerance, hypertension, and renal 
and cardiovascular disease (Peterson et al., 1990; Janssen et al., 1999; Phillips et al., 
1999). Thus, this animal model of T2DM develops a phenotype very similar to T2DM 
occurring in humans (Peterson et al., 1990), including the presence of microvascular 
complications, such as DN (Janssen et al., 1999; Phillips et al., 1999). Non obese and 
non-diabetic ZDF (+/+) rats were used as controls. The ZDF (+/+) rats remain 
normoglycaemic over time and do not display the metabolic and anatomic changes 
observed in the diabetic rats. 
 With the purpose to evaluate the therapeutic effect of sitagliptin as an anti-diabetic 
drug, in reverting/ameliorating some of the kidney lesions in diabetes, we treated diabetic 
ZDF rats with sitagliptin. It was shown that this oral anti-diabetic agent ameliorates the 
glycaemic control in T2DM patients and improves fasting and postprandial glycaemia by 
glucose-dependent insulin secretion (Ahren et al., 2002; Kim et al., 2005; Aschner et al., 
2006; Raz et al., 2006; Nonaka et al., 2007). 
 
 Body weight and glycaemia of diabetic (ZDF (fa/fa)) and non-diabetic (ZDF 
(+/+)) rats were monitored at the beginning (20 weeks old) and at the end (26 weeks old) 
of the study (Table 3). At 20 weeks, no significant differences in the body weight were 
observed between the groups. At the end of the study, 26 weeks of age, the diabetic 
animals presented a decrease of about 9% in their body weight (p<0.001 vs 20 weeks old 
ZDF (fa/fa), nevertheless the control animals ZDF (+/+) continued to gain weight. 
Treatment with sitagliptin stabilized the weight loss in the diabetic animals, preventing 
part of the body weight loss when compared with the ones without treatment (Table 3).  
No differences in food intake were found within each group throughout the 
treatment (data not shown). 
At the beginning of the study (20-weeks-old animals), the blood glucose levels of 
diabetic rats (304±17 mg/dl, p<0.001) were significantly higher when compared to their 
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age-matched controls (92±2 mg/dl). Hyperglycaemia was accompanied by a decline in 
insulin secretion as previously reported (Ferreira et al., 2010). At the beginning of the 
study, insulin levels were already significant lower in diabetic animals (13.7±0.9, p<0.01) 
when compared to their age-matched controls (15.0±5.9), and at the final time, the 
diabetic ZDF (fa/fa) rats exhibit relative insulinopaenia, comparatively to non-diabetic 
ZDF (+/+) rats. After the oral treatment with sitagliptin, blood glucose levels of diabetic 
animals (486±19 mg/dl, p<0.01) decreased significantly when compared to non-treated 
diabetic animals (523±16 mg/dl), as well as the insulinopaenic profile of diabetic animals 
(7.6±1.5, p<0.001) were significantly prevented (10.6±1.8) (Table 3). 
 
Table 3. Body weight and blood glucose levels throughout study in non-diabetic ZDF (+/+) and diabetic 
ZDF (fa/fa) rats non-treated and treated with 10 mg/kg/day sitagliptin, for 6 weeks. 
 Cont Diab Diab+Sita 
Age (weeks) 20 26 20 26 26 
Weight (g) 407±7 446±8 388±9 354±9*** 380±14 
Blood glucose (mg/dl) 92±2 89±3 304±17*** 523±16*** 486±19## 
Insulin (mU/L) 15.0±5.9 15.8±3.0 13.7±0.9** 7.6±1.5*** 10.6±1.8### 
 
Data are expressed as mean ± SEM (n ≥ 6 per group), *** p<0.001 and **p<0.01 significantly different 
from age-matched control, ## p<0.01 and ### p<0.001 significantly different from age-matched diabetic. 
ANOVA followed by Bonferroni’s post hoc test. 
 
The HbA1c levels were determined only at the end of the study, in 26-weeks-old 
animals (Figure 11). The diabetic group had significantly higher HbA1c levels 
(10.18±0.29%, p<0.001) than the control group (4.10±0.15%). Treatment with sitagliptin 
for 6 weeks in diabetic animals promoted a significant decrease of 1.2% (p<0.01) when 
compared with non-treated diabetic animals (Figure 11). 
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2. Sitagliptin decreases the protein levels of DPP-IV in the 
kidney of diabetic animals 
 CD26, the membrane form of DPP-IV enzyme, is widely distributed in numerous 
tissues, including the kidney. This enzyme is responsible for inactivating both GIP and 
GLP-1, inactivating the incretin effect (Mentlein et al., 1993). Therefore, DPP-IV 
inhibition potentiates endogenous incretin action by reduction its degradation. In fact, 
studies with DPP-IV knockout mice showed an increase in GIP and GLP-1 levels, as well 
as an improvement in glucose tolerance and enhanced insulin secretion (Marguet et al., 
2000). 
 In order to investigate the effect of sitagliptin on DPP-IV/CD26, its protein levels 
and distribution in the kidney were evaluated by Western Blottitng and 
immunohistochemistry, respectively (Figure 12). 
 
 Diabetes led to increased DPP-IV levels (244.26±29.14% of control, p<0.001) 
(Figure 12A). Sitagliptin treatment in the diabetic rats prevented the increase in kidney 
DPP-IV (146.03±15.66%; p<0.01) protein levels, compared to diabetic animals without 
treatment (Figure 12A). 
 Immunohistochemistry experiments performed in kidney frozen sections 
confirmed these results (Figure 12B). Diabetes led to a significant increase in DPP-IV 
immunoreactivity both in the glomerulus and cells around it, probably tubular cells. No 
staining was observed when the negative control for DPP-IV was performed, showing 
that the signal obtained is specific of the primary antibody used. Treatment with 
sitagliptin markedly decreased the staining for DPP-IV in the kidney of diabetic rats 
(Figure 12B). 
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Figure 11. HbA1c levels in non-diabetic ZDF (+/+) and diabetic ZDF (fa/fa) rats non-treated and 
treated with 10 mg/kg/day sitagliptin for 6 weeks, at 26 weeks of age. Data are expressed as mean ± 
SEM (n ≥ 6 per group), *** p<0.001 significantly different from control, ## p<0.01 significantly different 
from diabetic, ANOVA followed by Bonferroni’s post hoc test. 
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Figure 12. Sitagliptin prevents the upregulation of DPP-IV content in the kidney induced by diabetes. 
(A) The protein levels of DPP-IV were assessed in total kidney cell lysates by Western Blotting in ZDF 
(+/+) and ZDF (fa/fa) non-treated or treated with sitagliptin. The Western Blots presented are representative 
of each group of animals. Data are expressed as percentage of control and represent the mean ± SEM (n ≥ 6 
per group), *** p<0.001 significantly different from control, ## p<0.01 significantly different from 
diabetic, ANOVA followed by Bonferroni’s post hoc test. (B) Rpresentative confocal images for each 
group of animals showing DPP-IV immunoreactivity (green) and nuclear staining with DAPI (blue) in 
kidney sections. Magnification 400×. Legend: G - glomeruli, Arrows - tubular cells. 
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3. Sitagliptin modulates the incretin axis in the kidney of 
diabetic animals 
In order to investigate the effect of DPP-IV inhibition in the incretin axis, the 
content of GLP-1 protein was determined in total kidney extract by Western Blotting, as 
well as the distribution of this protein and their respective receptor (GLP-1R) in frozen 
kidney sections by immunohistochemistry (Figure 13). 
 
In diabetic animals, GLP-1 levels show a tendency to decrease (83.36±7.01%) 
compared to control group (100.00±5.78%), of about 16.64%. With sitagliptin 
administration, GLP-1 levels increased about 69.8% (159.74±28.39%, p<0.05) in diabetic 
animals, relatively to non-treated diabetic group (Figure 13A). 
By immunohistochemistry, we also observed a decreased immunoreactivity for 
GLP-1 in the diabetic kidneys. Treatment with sitagliptin increased GLP- 1 staining in 
diabetic animals (Figure 13B). Contrary to expected, although GLP-1R immunoreactivity 
is decreased in the kidney in response to diabetes, treatment with sitagliptin even 
accentuates this decrease in the glomeruli of the diabetic kidneys (Figure 13B). 
Additionally, the analysis of GLP-1 and GLP-1R co-staining also show some co-
localization of the two proteins, even in diabetic rats treated with sitagliptin (Figure 13C). 
This eventually suggests a possible binding of GLP-1 to its receptor, which can lead to 
activation of incretin downstream signaling from the receptor. 
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Figure 13. Effect of sitagliptin treatment in protein levels and distribution of GLP-1 and GLP-1R in 
the diabetic kidney. (A) The protein levels of GLP-1 were assessed in total kidney cell lysates by Western 
Blotting in ZDF (+/+) and ZDF (fa/fa) non-treated or treated with sitagliptin. The Western Blots presented 
are representative of each group of animals. Data are expressed as percentage of control and represent the 
mean ± SEM (n ≥ 6 per group), *p<0.05 significantly different from diabetic, ANOVA followed by 
Bonferroni’s post hoc test. (B) Representative confocal images for each group of animals showing GLP-1R 
immunoreactivity (green), GLP-1 immunorectivity (red) and nuclear staining with DAPI (blue) in the 
kidney sections. (C) Magnification of co-localization areas (Yellow). Original magnification 400×. Legend: 
G - glomeruli, Arrows - tubular cells. 
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4. Sitagliptin decreases the Akt activity in the kidney of 
diabetic animals 
 Previous studies from our group revealed that the obese diabetic (ZDF, fa/fa) rats 
of 26 weeks of age had a significant (p<0.001) increase in glomerular basement 
membrane thickening and glomerular atrophy, which was accompanied by an intense 
expression of mesangial expansion and Bowman’s capsule thickening (p<0.01), when 
compared with control animals (ZDF (+/+)) (Mega et al., 2011). In the group of diabetic 
animals treated with sitagliptin, there was an amelioration of these lesions, when 
compared to non-treated diabetic animals. Since it has previously described that 
mesangial cells hypertrophy and ECM expansion is associated with Akt activation 
(Zdychova and Komers, 2004; Alique et al., 2011; Kattla et al., 2008), we next intended to 
evaluate whether the improvement mediated by sitagliptin in renal lesions is mediated by 
this signaling pathway.  In this context, we evaluated the P-Akt levels in the kidney, by Western 
Blotting (Figure 14). 
 
As expected, the diabetic animals showed a significant increase in P-Akt protein 
levels (287.58±38.02%, p<0.001) relatively to control animals (100.00±18.43%), and the 
administration of sitagliptin decreased the P-Akt of about 110% (to 177.51±20.79%, 
p<0.05) as compared to non-treated diabetic animals (Figure 14), showing a possible 
connection between Akt signaling and renal lesions evolution, and also suggesting that 
sitagliptin could prevent this lesions by modulation of Akt activity.  
 
 
Figure 14. Effect of sitagliptin in P-Akt protein levels in the diabetic kidney. The protein levels of P-
Akt were assessed in total kidney cell lysates by Western Blotting in ZDF (+/+) and ZDF (fa/fa) non-treated 
or treated with sitagliptin, in, total kidney cell lysates. The Western Blots presented are representative of 
each group of animals. Data are expressed as percentage of control and represent the mean ± SEM (n ≥ 6 
per group), ***p<0.001 significantly different from control, # p<0.05 significantly different from diabetic, 
ANOVA followed by Bonferroni’s post hoc test. 
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5. Sitagliptin decreases the inflammatory state in the diabetic 
kidney 
 Several studies suggest that high glucose and lipid concentrations stimulate the 
production of proinflammatory cytokines (Donath et al., 2008; Ferreira et al., 2010). 
Moreover, it has been shown that the inflammatory state is relevant in the pathogenesis of 
DN (Saraheimo et al., 2003; Dalla Vestra et al., 2005) and  improvement of renal lesions 
has been described as being  associated with an amelioration of the inflammatory state 
(Ferreira et al., 2010). Recent studies performed in our laboratory, in the same animal 
model, demonstrated that diabetes increased serum levels of IL-1β and TNF, and that 
sitagliptin administration significantly decreased the IL-1β levels (Ferreira et al., 2010). 
The proinflammatory cytokines IL-1β and TNF are thought to contribute to an 
inflammatory response in diabetic kidney (Hasegawa et al., 1995). Therefore, we 
performed a qualitative analysis to evaluate the cellular distribution for these 
proinflammatory cytokines in kidney frozen sections by immunohistochemistry (Figure 
15). 
 
 Diabetes markedly increased the immunoreactivity of IL-1β and TNF in cells 
around the glomeruli that are probably tubular cells and/or accumulation of interstitial 
inflammatory cells. The administration of sitagliptin improves the protein levels of IL-1β 
and TNF in the diabetic kidney (Figure 15). Furthermore, the increase in the 
immunoreactivity for these cytokines in the kidney of diabetic rats may also be due to the 
recruitment and accumulation of interstitial inflammatory cells infiltrations, such as 
macrophages, monocytes and T cells (Chow et al., 2004; Xiao et al., 2009). 
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Figure 15. Sitagliptin decreases the proinflammatory cytokines IL-1β and TNF-α in the diabetic 
kidney. Representative confocal images for ZDF (+/+) and ZDF (fa/fa) non-treated or treated with 
sitagliptin, showing IL-1β immunoreactivity (green), TNF-α immunorectivity (red) and nuclear staining 
with DAPI (blue) in kidney sections. Magnification 400×. Legend: G - glomeruli, Arrows - tubular cells. 
 
6. Effects of diabetes and sitagliptin treatment in ER stress 
response in the kidney 
 There are several reports in the literature implicating the ER stress in several 
pathologies, including diabetes, by being involved in pancreatic β-cells loss and insulin 
resistance (Araki et al., 2003). Furthermore, altered metabolic conditions associated with 
diabetes can lead to UPR response, leading to apoptosis and inflammation (Kaneto et al., 
2006), which contribute for the development of diabetic complications, namely DN 
(Lindenmeyer et al., 2008). Therefore, we want evaluate the protein levels of CHOP, 
since this transcription factor plays an important role in ER stress-mediated apoptosis 
(Nishitoh, 2012), whose induction strongly depends on ATF4, another transcription factor 
activated by PERK pathway. Furthermore, we also intended to evaluate how GRP78/BiP 
is regulated, which is an important ER chaperone involved in UPR activation. 
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 As a first approach, we performed a quantitative analysis for CHOP protein by 
Western Blotting, in the kidney total extracts of non-diabetic ZDF (+/+) rats and diabetic 
ZDF (fa/fa) rats treated and non-treated with sitagliptin (Figure 16). 
 Contrary to the expected, the administration of sitagliptin significantly increase 
CHOP levels in the diabetic ZDF (fa/fa) rats (163.26±11.03%, p<0.001), comparatively to 
non-treated diabetic (107.27±5.47%) and non-diabetic animals (100.00±6.09%) (Figure 
16A). These results were confirmed by immunohistochemistry analysis in the kidney, 
showing that, although diabetes induced a slightly increase in immunoreactivity for 
CHOP, the increase in the staining was more evident when diabetic rats were treated with 
sitagliptin (Figure 16B). 
 
 
Figure 16. Effect of sitagliptin treatment in protein levels and distribution of CHOP in diabetic 
kidney. (A) The protein levels of CHOP were assessed in kidney total cell lysates by Western Blotting, in 
ZDF (+/+) and ZDF (fa/fa), non-treated or treated with sitagliptin, total kidney cell lysates. The Western 
Blots presented are representative of each group of animals. Data are expressed as percentage of control and 
represent the mean ± SEM (n ≥ 6 per group), ***p<0.001 significantly different from control, ### p<0.001 
significantly different from diabetic, ANOVA followed by Bonferroni’s post hoc test. (B) Representative 
confocal images for each group of animals showing CHOP immunoreactivity (red) and nuclear staining 
with DAPI (blue) in the kidney sections. Magnification 400×. Legend: G - glomeruli, Arrows - tubular 
cells. 
 
Since we did not observe significant changes in total CHOP protein levels in 
response to diabetes, we hypothesized that this protein, which is a transcription factor 
involved in the ER stress response, could be redistributed in the cell, increasing its 
content in the nuclear fraction. In order to test this hypothesis, we performed a subcellular 
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fractionation of the kidney and evaluated the levels of CHOP and another ER stress 
transcription factor, ATF4, in nuclear and cytoplasmic fractions in the kidney of the three 
groups of animals. 
 Preliminary results seemed to indicate that there was a subcellular redistribution of 
CHOP in response to diabetes (Figure 17).  There was an increase in CHOP protein levels 
in the nuclear fraction of diabetic kidney with a paralleled decrease in its content in the 
cytosolic fraction (Figure 17). We also observed similar results for another transcription 
factor associated with the ER stress, ATF4 (Figure 17). Although there was an increase in 
the total amount of CHOP protein in diabetic rats treated with sitagliptin, results of cell 
fractionation indicated that CHOP, and also ATF4, seemed to accumulate preferentially 
in the cytosolic fraction (Figure 17). 
 
 
Figure 17. Effect of diabetes and sitagliptin in intracellular distribution of CHOP and ATF4 in the 
kidney. The protein levels of CHOP and ATF4 were assessed in subcellular fractions of the kidney by 
Western Blotting in ZDF (+/+) and ZDF (fa/fa) non-treated or treated with sitagliptin. The Western Blots 
presented are representative of each group of animals. Preliminary data (n = 1 per group). 
 
GRP78/BiP is essential for UPR signaling cascade activation, through activation 
of the three ER stress sensors, namely IRE1α, PERK and ATF6, and is the central 
regulator of ER function and homeostasis (Schrӧder and Kaufman, 2005; Ni and Lee, 
2007). There has been described that during ER stress response, the protein levels of 
GRP78/BiP increase, since the UPR is associated with an up-regulation of ER chaperone 
proteins, such as GRP78/BiP (Kozutsumi et al., 1988). 
In an attempt to correlate the observed protein levels in kidney for CHOP with the 
UPR signaling cascade activation, a Western Blotting analysis to evaluate the protein 
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levels of GRP78/BiP was performed. However, no significant differences were observed 
between groups (Figure 18).  
 
 
Figure 18. Effect sitagliptin treatment in protein levels of GRP78/BiP in the diabetic kidney. (A) The 
protein levels of GRP78/BiP were assessed in kidney total cell lysates by Western Blotting in ZDF (+/+) 
and ZDF (fa/fa) non-treated or treated with sitagliptin. The Western Blots presented are representative of 
each group of animals. Data are expressed as percentage of control and represent the mean ± SEM (n ≥ 6 
per group), ANOVA followed by Bonferroni’s post hoc test. 
 
7. Sitagliptin protects the diabetic kidney against apoptotic cell 
death induced by diabetes 
 The progressive decline in renal function is associated with renal cells loss, such 
as glomerular and tubular cells. Therefore, in order to evaluate the apoptotic state in the 
diabetic kidney, the content of the pro-apoptotic proteins BAX and Bid, as well as the 
anti-apoptotic protein Bcl-2 was determined. 
 It is well established that the ratio between BAX and Bcl-2 determines the 
response to a cell death signal, being considered an indicator for the activation of 
apoptosis (Xiang et al., 1996). The levels and subcellular distribution of pro-apoptotic 
protein BAX were determined by Western Blotting and immunohistochemistry, and the 
content of anti-apoptotic protein Bcl-2 was determined by Western Blotting, in total 
kidney of ZDF (+/+) and ZDF (fa/fa) rats. 
The results exhibited in Figure 19 show a significant increase (p<0.01) in BAX/Bcl-2 
ratio in diabetic animals when compared to control group. The administration of 
sitagliptin improves (p<0.05) the pro-apoptotic state induced by diabetes (Figure 19A). A 
significant increase in immunoreactivity for the pro-apoptotic protein BAX in the kidney 
of diabetic ZDF (fa/fa) rats was observed, and there seems to be a subcellular 
redistribution of protein, which decreases with sitagliptin treatment, mainly in glomerulus 
(Figure 19B). 
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Figure 19. Effect of sitagliptin treatment in protein levels of BAX and Bcl-2 and subcellular 
distribution of BAX in the diabetic kidney. (A) The protein levels of BAX and Bcl-2 were assessed in 
kidney total cell lysates by Western Blotting in ZDF (+/+) and ZDF (fa/fa) non-treated or treated with 
sitagliptin. The Western Blots presented are representative of each group of animals. Data are expressed as 
the mean ± SEM (n ≥ 6 per group), **p<0.01 significantly different from control, # p<0.05 significantly 
different from diabetic, ANOVA followed by Bonferroni’s post hoc test. (B) Representative confocal 
images for each group of animals showing BAX immunoreactivity (green) in the kidney sections. 
Magnification 400×. Legend: G - glomeruli, Arrows - tubular cells. 
 
During apoptosis, an important pathway leading to caspase activation involves the 
release of cytochrome c from the intermembrane space of mitochondria, by 
permeabilization of the outer mitochondrial membrane, and it has been described that Bid 
protein, a pro-apoptotic member of the Bcl-2 family, induces the release of cytochrome c, 
leading to cell apoptosis (Kluck et al., 1999). 
 By Western Blotting analysis, it was observed that diabetes also induces a 
significant increase in Bid levels (173.57±22.64%, p<0.01), as observed for BAX, of 
about 73.57% comparatively to non-diabetic ZDF (+/+) rats (100.00±15.33%). Treatment 
with sitagliptin decreased the levels of Bid in diabetic animals by about 60.55% 
(113.02±9.43%), relatively to non-treated animals (p<0.05) (Figure 20). 
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Figure 20. Effect of sitagliptin in protein levels of Bid in the diabetic kidney. The protein levels of Bid 
were assessed in kidney total cell lysates by Western Blotting in ZDF (+/+) and ZDF (fa/fa) non- treated or 
treated with sitagliptin. The Western Blots presented are representative of each group of animals. Data are 
expressed as percentage of control and represent the mean ± SEM (n ≥ 6 per group), **p<0.01 significantly 
different from control, # p<0.05 significantly different from diabetic, ANOVA followed by Bonferroni’s 
post hoc test. 
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Discussion 
Diabetic nephropathy (DN) is one of the major microvascular complications of 
diabetes and it is currently the leading cause of ESRD (Dronavalli et al., 2008; Kanwar et 
al., 2008), conferring high morbidity and mortality rates of diabetic patients. About 20-
40% of patients with diabetes develop evidence of nephropathy (Dronavalli et al., 2008), 
and due to the increase of global prevalence of DM in recent years (IDF, 2012), it 
becomes imperative to implement effective therapeutic strategies for diabetes treatment. 
Given that a good glycaemic control reduces the risk for the development of diabetic 
complications, the search of new glucose-lowering agents for treatment for T2DM is 
particularly highly regarded.  
GLP-1 is responsible for most of the incretin effect, which in non-diabetic 
individuals is a physiological action. However, in T2DM patients the incretin effect is 
blunted “incretin defect”. The “incretin defect”, a metabolic deterioration associated with 
T2DM was demonstrated by Nauck et al., (1986). In their study, oral and intravenous 
glucose caused similar changes in plasma glucose concentration in subjects with T2DM. 
In healthy individuals, insulin secretory response after oral glucose ingestion exceeded 
the response elicited by intravenous administration of an equal amount of glucose. So, in 
non-diabetic individuals, there was a difference between the response to an intravenous 
and an oral glucose administration due to the “incretin effect”. For individuals with 
T2DM, this effect was diminished after oral administration of glucose and the plasma 
glucose values obtained by oral and intravenous administration were similar. Taking into 
consideration that in diabetes there is an increased activity of DPP-IV (enzyme 
responsible for incretin degradation) and consequently, a remarkably decrease of incretin 
action, the use of incretin mimetics, such as GLP-1 analogues, or incretin enhancers, such 
as DPP-IV inhibitors, would cope with the deficit in incretin system. Sitagliptin is a 
selective DPP-IV inhibitor for treatment of patients with T2DM, improving fasting and 
postprandial glycaemia and deceasing HbA1c levels (Herman et al., 2007). Sitagliptin is a 
well-tolerated oral anti-diabetic agent, neutral concerning changes of weight with low 
propensity to cause hypoglycaemia (Drucker and Nauck, 2006). However, the sitagliptin 
efficacy in restoring kidney function, in conditions of chronic hyperglycaemia, in terms of 
improvement of inflammatory state and cell death, as well as in modulation of ER stress 
response, either by decreasing blood glucose levels or by extrapancreatic action of 
incretins in an independent manner of increased insulin secretion, remains unclear.  
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Our group has recently shown that the DPP-IV inhibitor sitagliptin has a positive 
impact on the retinal barrier and prevents inflammatory and pro-apoptotic states triggered 
by diabetes in the retina (Gonçalves et al., 2011). Other authors have already suggested 
cytoprotective effects of sitagliptin on other tissues and conditions, including on 
cardiovascular disorders as well as on kidney disease (Read et al., 2010; Vaghasiya et al., 
2010; Mega et al., 2011; Matsubara et al., 2013; Apaijai et al., 2013). This study aims to 
determine the putative benefits of sitagliptin treatment in the diabetic kidney, and the 
underlined mechanisms, using the Zucker Diabetic Fatty (ZDF) rats as T2DM model, the 
same diabetic animal model that was used in the work described before. 
 DN in human patients is characterized by renal hypertrophy, hyperfiltration, 
proteinuria and progressive glomerulosclerosis (Kanwar et al., 2008). Accordingly to 
previous studies, ZDF (fa/fa) rats show a significant renal hypertrophy at 20 weeks of 
age, as well as loss of kidney function (Mega et al., 2011), thus, this animal model seems 
to be useful for evaluation of the effects of sitagliptin treatment in the diabetic kidney and 
their benefits in the prevention or reduction of some of the lesions present in DN. 
 Our results show that the chronic treatment with sitagliptin provided a significant 
decrease of insulin levels, plasma glucose and HbA1c, and also prevent the weight loss, 
characteristic of a more advanced stage of T2DM, which confirms the results obtained in 
studies performed in humans (Ahren et al., 2002; Kim et al., 2005; Aschner et al., 2006; 
Raz et al., 2006; Nonaka et al., 2007) and rats (Mega et al., 2011). 
 In an attempt to clarify the hypothesis that sitagliptin improves the glycaemic 
control by inhibition of DPP-IV, leading to enhance of incretins effect, we started to 
evaluate the DPP-IV protein levels and the subcellular distribution in the kidney sections, 
of non-diabetic ZDF(+/+) rats, and treated and untreated diabetic ZDF(fa/fa) rats. DPP-IV 
is widely distributed in numerous tissues and cells, and its enzymatic activity is exhibited 
in both membrane-anchored cell-surface peptidase and as a smaller soluble form in blood 
plasma. In this study, DPP-IV protein levels were assessed in the kidney tissue, through 
the membrane form, also called CD26. To confirm that DPP-IV inhibition leads to 
accumulation of GLP-1, we also determine the content of GLP-1 in the kidney, since 
DPP-IV degrades this incretin hormone. 
 Our results show that diabetes induces an increase in kidney DPP-IV protein 
levels, when compared to non-diabetic animals. Accordingly to our results, it was 
reported in a streptozotocin (STZ)-induced diabetic model that STZ enhanced the 
expression of Dpp-IV mRNA in the kidney tissue (Kirino et al., 2009). There are also 
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some reports suggesting that microvascular endothelial cells are the main sources of 
endogenous DPP-IV (Matheeussen et al., 2011). In fact, in an in vitro study, both Dpp-IV 
mRNA expression and DPP-IV activity were enhanced by exposure of human glomerular 
endothelial cells to high glucose (Pala et al., 2003). Furthermore, work performed by 
Kirino et al. (2009) also confirms that STZ-induced diabetes enhances the enzyme 
activity of circulating DPP-IV. These findings suggest an increase in the plasma DPP-IV 
activity trough the enhancement of DPP-IV expression induced by high blood glucose. 
So, although DPP-IV enzyme activity was not evaluated in this study, we can speculate 
that in diabetic ZDF (fa/fa) rats the circulating DPP-IV inhibitory activity might be 
enhanced, since DPP-IV protein levels were higher than in non-diabetic ZDF (+/+) rats. 
To prove this hypothesis, we evaluate protein levels and subcellular distribution of GLP-
1. The GLP-1 protein levels in diabetic ZDF (fa/fa) rats, although with no significant 
differences from non-diabetic animals, seem that trend to decrease. Kirino et al. (2009) 
study reports a decrease in DPP-IV enzyme activity in the kidney of STZ-induced 
diabetes, despite increased Dpp-IV mRNA expression. This could be explained by the fact 
that hyperglycaemia-induced renal endothelial cell damage could cause the leakage of 
microvascular endothelial DPP-IV enzyme of the kidney into the circulation, as suggested 
by Kirino et al. (2009) and other previous reports (Augustyns et al., 1999; Pala et al., 
2003). This release of DPP-IV from the kidney into the circulation could contribute to the 
increase in the circulating DPP-IV enzyme activity, with a paralleled reduction in the 
kidney tissue. Therefore, this decrease in DPP-IV enzyme activity in the kidney could 
explain why there are any significant differences in GLP-1 protein levels. 
Sitagliptin treatment promoted a significant decrease in DPP-IV protein levels in 
the diabetic kidney. Given that high glucose levels enhance Dpp-IV mRNA expression 
(Pala et al., 2003), the decrease of DPP-IV levels in the kidney could be related to the 
sitagliptin-induced decrease in blood glucose levels, through enhancement of incretins 
insulinotropic effect.  
To prove DPP-IV inhibition by sitagliptin we evaluated indirectly DPP-IV 
enzymatic activity via evaluation of GLP-1 protein levels. As expected, the 
administration of sitagliptin markedly increases the GLP-1 protein levels in the kidney of 
diabetic ZDF (fa/fa) rats. This could confirm the inhibitory efficacy of DPP-IV induced 
by sitagliptin, but to establish the relation between GLP-1 degradation to DPP-IV more 
studies have to be performed, which could be determine with glp-1 mRNA analysis. 
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Additionally, our results show that diabetes seems to decrease GLP-1R protein 
levels in the kidney, accordingly to other reports (Mima et al., 2012). But with 
administration of sitagliptin the immunoreactivity for GLP-1R in the kidney markedly 
decreases, which are not in agreement with other reports (Liu et al., 2011). The decreased 
GLP-1R immunoreactivity could be related to a negative feedback. The markedly 
increase in GLP-1 protein levels in the diabetic kidney following sitagliptin 
administration could lead to a decrease in GLP-1R expression and/or degradation, in 
order to maintain cell homeostasis. 
 As previously referred, DN is a progressive renal disease, characterized by 
functional and structural abnormalities in the kidney. The morphological changes of the 
kidney include glomerular and tubular epithelial hypertrophy, thickening of GBM and 
expansion of mesangial ECM (Adler, 1994; Chawla et al., 2010). There has been 
described that Akt signaling pathway has an emerging role in the development of renal 
lesions, such as mesangial hypertrophy and ECM composition (Zdychova and Komers, 
2004; Alique et al., 2011; Kattla et al., 2008).  
 Akt is a serine/threonine kinase that regulates a variety of cellular processes, 
including survival, proliferation, protein translation and metabolism (Manning and 
Cantley, 2007). Akt can be activated in response to insulin or a wide variety of growth 
stimuli, such as growth factors and insulin, and represent an important intermediate in 
insulin signaling. Akt activation typically occurs via tyrosine kinase receptors in a 
phosphatidylinositol 3-kinase (PI3K)-dependent manner (Downward, 1998). The 
activation of PI3K stimulates the production of phosphatidyl-inositol 3-phosphate (PI3P), 
which binds to pleckstrin homology (PH) domain of Akt triggering its translocation to the 
plasma membrane (Franke et al., 1997). Once in correct position in the membrane, Akt 
can be phosphorylated by 3-phosphoinositide dependent protein kinases (PDKs) at 
threonine 308 (Thr308) and serine 473 (Ser473) residues (Alessi et al., 1997; Bellacosa et 
al., 1998). Then, activated (phosphorylated) Akt becomes available for phosphorylation 
of its downstream targets. 
In this study, we observed that P-Akt protein levels significantly increase in the 
diabetic kidney, in agreement with previous reports (Feliers et al., 2001; Zdychova et al., 
2008), suggesting that PI3K/Akt signaling pathway is involved in ECM accumulation and 
mesangial cells hypertrophy. Being a growth factor, TGF- β1 could activate the PI3K/Akt 
pathway in various cells, including the kidney. Therefore, the increased in P-Akt protein 
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levels in DN could be explained by TGF-β1 (Kattla et al., 2008), which is overexpressed 
in diabetic kidney (Yamamoto et al., 1993). But further studies should address if this 
mechanism is involved in the data obtained by us. 
Previous studies of our group have showed that obese diabetic (ZDF, fa/fa) rats 
develop kidney lesions characterized by increased glomerular basement membrane 
thickening and glomerular atrophy, accompanied by an intense expression of mesangial 
expansion and Bowman’s capsule thickening (Mega et al., 2011). These lesions showed a 
trend to improvement in the sitagliptin-treated diabetic animals, when compared to non-
treated animals. Therefore, mesangial expansion showed a 37.5% reduction in the most 
severe grade, glomerular atrophy and glomerular basement membrane presented a 25% 
and 12.5% reduction, respectively (Mega et al., 2011). Our data demonstrate that 
sitagliptin-evoked amelioration in renal lesions was accompanied by a decrease of P-Akt 
levels. Together, these results suggest that the PI3K/Akt signaling pathway might be 
deeply involved in the progression of renal lesions in the diabetic kidney, and that 
sitagliptin treatment improved these lesions by mechanisms related to the PI3K/Akt 
pathway.  
Some mechanisms have been proposed to be implicated in Akt-induced renal 
lesions in DN, such as the Akt/mTOR pathway (Zdychova et al., 2008; Nagai et al., 
2005). Mammalian target of rapamycin (mTOR) is one of the down-stream targets of Akt, 
which directly phosphorylates mTOR; in addition, activated mTOR is involved in the 
regulation of protein synthesis, promoting cell growth (i.e. an increase in cell mass) (Scott 
et al.1998). Therefore, several studies show that Akt/mTOR pathway is implicated in 
mesangial cell hypertrophy (Zdychova et al., 2008; Nagai et al., 2005).  
Few is Known about the mechanisms implicated in the putative renoprotective 
effects of sitagliptin in DN. Our results show that the improvement of renal lesions could 
be related with the sitagliptin-induced decrease in activated Akt, as well as with the 
improvement of inflammatory state and cell death by apoptosis, which will be discussed. 
Accumulating evidences also points to the critical role of the inflammatory state in 
the development of diabetic complications, suggesting that microvascular inflammation is 
a common mechanism in the pathogenesis of DN (Saraheimo et al., 2003; Dalla Vestra et 
al., 2005). Therefore, there is an increased expression of proinflammatory cytokines in 
the diabetic kidney, such as IL-1β and TNF (Navarro et al., 2006), leading to enhanced 
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vascular endothelial permeability, oxidative stress, renal hypertrophy and 
tubulointerstitial lesions (Lim and Tesch, 2012).  
Recently, it has been reported that in the kidney of ZDF (fa/fa) rats the expression 
of VCAM-1 increases with concomitant infiltration of white blood cells, as well as 
enhanced production of inflammatory cytokines, such as TNF and IL-1β, leading to renal 
cells injury (Wang et al., 2012). Our study also shows an increase in proinflammatory 
cytokines, IL-1β and TNF, in the diabetic kidney, mainly in cells around the glomeruli, 
probably tubular cells and/or accumulation of interstitial inflammatory cells. In the group 
of diabetic rats under sitagliptin therapy, an accentuated decrease in these 
proinflammatory cytokines was found. These results, obtained by immunohistochemistry 
in the kidney sections, seem to be in agreement with results obtained in our group, which 
report a decreased of IL-1β and TNF serum levels in ZDF (fa/fa) rats treated with 
sitagliptin (Ferreira et al., 2010). Together, these results demonstrate that a chronic 
sitagliptin treatment corrected the inflammatory state in diabetic kidney, as well as in 
other diabetic microvascular complications, such as diabetic retinopathy, which was also 
described by our group (Gonçalves et al., 2011). Moreover, several studies have shown 
that the decrease in inflammation promotes an amelioration of renal injuries (Yozai et al., 
2005; Tone et al., 2005; Wu et al., 2006; Mega et al., 2011). 
Inflammatory cells, such as macrophages, lymphocytes and monocytes (Lim and 
Tesch, 2012), are often found in tubular compartment (Mezzano et al., 2003). In fact, 
there are reports of infiltration of mononuclear cells in the kidney of patients with DN 
(Furuta et al., 1993), showing that interstitial inflammatory cells infiltrates are associated 
with progression of renal injuries in DN (Chow et al., 2004; Ninichuk et al., 2007). MCP-
1 played a key role in promoting recruitment and infiltration of macrophage in the 
diabetic kidney (Tesch et al., 2008), and there has been described that hyperglycaemia 
increases expression of MCP-1 in tubular cells of the diabetic kidney (Mezzano et al., 
2003; Chow et al., 2006). The proinflammatory transcription factor NF-κB was also 
detected mainly in tubular cells of human and rat kidney, with T2DM and overt 
nephropathy (Morcos et al., 2002). Furthermore, the NF-κB regulates the gene expression 
of several molecules involved in inflammation, which includes MCP-1, IL-1β and TNF 
(Guijarro and Egido, 2001). Based on these evidences, the NF-κB and MCP-1 increased 
expression in tubular cells of diabetic kidney can be a plausible explanation for our 
results, but to clarify this hypothesis further studies are required. 
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ER stress has been suggested as one of the underlying mechanism in the 
pathogenesis of several diseases, namely atherosclerosis, and neurodegenerative and 
metabolic diseases, such as diabetes (Malhotra and Kaufman, 2007). Some studies have 
reported that ER stress-mediated apoptosis is implicated in renal injury onset in diabetes 
(Liu et al., 2008; Lim et al., 2010). Given that CHOP protein plays an important role in 
pro-apoptotic pathway of UPR (Nishitoh, 2012), we intended to evaluate the possible 
association between renal cells apoptosis and ER stress response, by studying CHOP-
mediated apoptosis. It has been described that one of the mechanisms involved in CHOP-
mediated apoptosis involves increased BAX/Bcl-2 ratio, with down-regulation of Bcl-2 
expression, and translocation of BAX to the mitochondria (McCullough et al., 2000; 
Gotoh et al., 2004). Therefore, as a first approach we determined the BAX/Bcl-2 ratio in 
the diabetic kidney, whose results demonstrated that diabetes significantly increases this 
ratio, supporting the hypothesis that diabetes-induced activation of CHOP-mediated 
apoptosis in the kidney could be implicated in DN progression. However, it is important 
to note that ER stress-mediated apoptosis could also be related with JNK-mediated and 
caspase-mediated pathways (reviewed in Inagi, 2009). 
ER stress is also implicated in inflammatory state in the kidney, which is proved 
by the fact that ER stress attenuation decreases the expression of proinflammatory 
cytokines in diabetic kidney (Qi et al., 2010). The signaling pathways in the UPR and 
inflammation are interconnected through diverse mechanism, including the production of 
ROS and activation of NF-κB and JNK (Zhang and Kaufman, 2008). Therefore, the 
increase in the proinflammatory transcription factor NF-κB levels in the kidney, as 
described above (Morcos et al., 2002), could be linked to ER stress response. Moreover, 
the increase in the proinflammatory cytokines TNF and IL-1β protein levels in the 
diabetic kidney could be related to UPR activation. However, in order to clarify this issue 
further studies are required. Additionally, CHOP has been suggested to be a key 
molecule, not only in apoptosis, but also in inflammatory response, since UPR-induced 
CHOP expression is implicated in the processing of pro-IL-1β (Endo et al., 2006). 
Given all these findings, we attempted to investigate relationship between 
apoptosis and inflammation in the diabetic kidney, with the UPR activation, through 
analysis of CHOP protein levels. Contrary to the expected, there were not any significant 
differences in the protein levels of CHOP in the total protein extracts of diabetic kidney, 
comparatively to non-diabetic animals. It is well known that the switch of pro-survival to 
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pro-apoptotic ER stress response is dependent of the duration and degree of ER stress. In 
fact, Rutkowski et al. (2006) reported in a cell culture system that a chronic exposure to a 
mild stress can lead to an adaptive ER stress response, as a consequence of the intrinsic 
instabilities of mRNAs and proteins that promote apoptosis, compared to those that 
facilitate protein folding and adaptation. Furthermore, this study demonstrates in this cell 
system that the up-regulation peaked of CHOP expression is after approximately 16h of 
treatment with stress-inducers (e.g. tunicamycin), and was diminished by 24h. Therefore, 
we cannot exclude the hypothesis that, in our work, the up-regulation peak of CHOP in 
the diabetic kidney happened before the end of the study (at 26 weeks of age). In addition, 
it is also possible that, at this age, CHOP expression in kidney cells is suppressed or 
attenuated, by degradation of CHOP mRNA and/or CHOP protein (Rutkowski et al., 
2006). Although no differences were shown in total protein levels, preliminary data seems 
to indicate that diabetes favors both CHOP and ATF4 translocation to the nucleus. 
Despite there is no up-regulation of CHOP expression at this age, this seems to indicate 
that translocation of this transcription factor to the nucleus may be related to the up-
regulation of transcription of pro-apoptotic factors and down-regulation of transcription 
of anti-apoptotic factors. 
Usually, in stress conditions, the GRP78/BiP is up-regulated, due to UPR 
activation. However, in agreement with the results for CHOP protein levels, the ER 
chaperone GRP78/BiP did not present significant differences in the kidney of diabetic and 
non-diabetic animals. GRP78/BiP is the best characterized ER chaperone protein. It is a 
central regulator of ER function due to its roles in folding and assembly of newly-
synthesized proteins, regulating calcium homeostasis and serves as a sensor for ER stress, 
as well as targeting misfolded protein for proteasome degradation (Lee, 2001). The result 
for GRP78/BiP protein levels could be related to be related to autophagy, as well as with 
activation of ERAD, which can lead to an adaptive ER stress response, as said before. 
ERAD is a process by which misfolded ER proteins are detected, preventing them from 
processing along secretory pathway, and then performing their retro-translocation to 
cytosol where they undergo ubiquitin- and proteasome-dependent degradation (Meusser 
et al., 2005). Autophagy is a cellular process involving the degradation of damage 
organelles/proteins through the lysossomal machinery, allowing the maintenance of 
homeostasis by helping the balance between the synthesis, degradation and subsequent 
recycling of macromolecules and organelles. Therefore, these processes could alleviate 
the misfolded protein accumulation in the ER lumen leading to amelioration in ER stress, 
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and so activation of the proximal sensors of ER stress becomes suppressed, as well as 
GRP78/BiP expression, which could explain the results obtained for GRP78/BiP protein 
levels in the diabetic kidney. In fact, a recent study has shown that ER stress induces 
autophagy in tubular cells, as a protection against cell death (Pallet et al., 2008). But 
further studies are needed to elucidate the role of autophagy associated with ER stress in 
this animal model, and if autophagy is cytoprotective response to ER stress by removing 
the overload of unfolded or misfolded protein that exceeds the ER capacity.  
Interestingly, the administration of sitagliptin significantly increases CHOP 
protein levels in the kidney of diabetic ZDF (fa/fa) rats. In fact, activation of GLP-1R 
improved β-cells survival upon induction of ER stress by a mechanism involving increase 
of ATF4/CHOP expression has been previously reported (Yusta et al., 2006). This result 
confirms that the enhancement of incretin effect increases cellular defense mechanism, 
decreasing the pro-apoptotic state, besides the effect in insulin secretion. Our preliminary 
data of total CHOP protein levels and subcellular fractionation of CHOP and ATF4 
proteins, determined by Western Blotting, go against this hypothesis. Although sitagliptin 
administration significantly increased the CHOP protein levels in the kidney of diabetic 
ZDF (fa/fa), the translocation of CHOP and ATF4 to the nucleus decreases. Therefore, 
the expression of pro-apoptotic factors decreases, accompanied with improvement in cell 
death by apoptosis, which is consistent with our results. Thereby, we can hypothesize that 
GLP-1R activation or direct GLP-1 effects, can block CHOP and ATF4 translocation, but 
to prove that more studies are required. 
Based on the study performed by Yusta et al. (2006), the up-regulation of CHOP 
protein that we observed in the kidney of diabetic animals treated with sitagliptin, could 
be related with the activation of GLP-1R. The GLP-1R activation leads to induction of 
the transcriptional activator ATF4 in a cAMP- and PKA-dependent manner (Yusta et al., 
2006). This will also enhance the expression of its downstream targets, such as CHOP, as 
well as GADD34, that would lead to eIF2α dephosphorylation and a more rapid recovery 
of global protein synthesis. However, further experiments have to be performed to prove 
this hypothesis or determined the mechanism that underlies this fact. But it is noteworthy 
that this coupling of GLP-1R signaling pathways to modulate ER stress response could 
represent a promising therapeutic strategy. 
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Conclusion 
 In the present study, we confirm the deleterious effects of diabetes in the kidney, 
resulting in cell death by apoptosis, increase inflammation and progression of kidney 
injuries, namely ECM expansion and mesangial hypertrophy. These are accompanied by 
increased DPP-IV protein levels. Administration of sitagliptin restored DPP-IV levels 
towards those in the control group and markedly increased the GLP-1 protein levels in the 
diabetic kidney. 
The sitagliptin treatment was able to ameliorate nephropathy induced by diabetes 
in ZDF (fa/fa) rats, a T2DM model, as shown by significant reduction in inflammatory 
state and cell death by apoptosis. Sitagliptin seems also to be implicated in ER stress 
modulation. 
 In conclusion, it is plausible that the incretin modulator sitagliptin could be used 
in the prevention/reversion of diabetic nephropathy progression, as well as in the 
management of T2DM and its complications. However, further studies are needed to 
better understand the molecular and cellular mechanisms involved in the direct actions 
mediated sitagliptin in the kidney, which may contribute to the development of new 
therapeutic strategies more effective and focused on preventing or reducing the injurious 
effect of chronic hyperglycaemia on cells of the kidney. 
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